

From The Department of Microbiology, Tumor and Cell Biology,
Karolinska Institutet, Stockholm, Sweden

THE ROLE OF VEGF FAMILY IN ANGIOGENESIS, TUMOR GROWTH AND METASTASIS

Xiaojuan Yang



**Karolinska
Institutet**

Stockholm 2014

All previously published papers were reproduced with permission from the publisher.

Published by Karolinska Institutet.

Printed by ÅTTA.45 TRYCKERI AB

© Xiaojuan Yang, 2014

ISBN 978-91-7549-754-9

THE ROLE OF VEGF FAMILY IN ANGIOGENESIS,
TUMOR GROWTH AND METASTASIS
THESIS FOR DOCTORAL DEGREE (Ph.D.)

By

Xiaojuan Yang

Thesis defense

Date and time: 14:00 on Tuesday, December 9, 2014

Venue: Föreläsningssal Petrén, Nobels väg 12B, Karolinska Institutet

Principal Supervisor:

Professor Yihai Cao
Karolinska Institutet
Department of Microbiology, Tumor and Cell
Biology

Opponent:

Doctor Jenny L Persson
Lund University
Department of Laboratory Medicine
Division of Experimental Cancer Research

Co-supervisor(s):

Doctor Kayoko Hosaka
Karolinska Institutet
Department of Microbiology, Tumor and Cell
Biology

Examination Board:

Doctor Charlotte Rolny
Karolinska Institutet
Department of Oncology-Pathology

Professor Laszlo Szekely
Karolinska Institutet
Department of Microbiology, Tumor and Cell
Biology

Professor Keiko Funa
University of Gothenburg
Sahlgrenska Cancer center
Institute of Biomedicine

给梦想医始的我们.....

ABSTRACT

Tumor growth is dependent on angiogenesis, and cells in tumor tissues produce various angiogenic factors to induce neovascularization. Among tumor-derived angiogenic factors, members of the vascular endothelial growth factor (VEGF) family are most frequently and highly expressed in various solid tumors. VEGF-A, the prototype of VEGF, is the most powerful pro-angiogenic factor that binds to VEGF receptor-1 (VEGFR-1, also called FMS-Related Tyrosine Kinase-1/Flt-1) and VEGFR-2 (also called Kinase Insert Domain Receptor/KDR or Fetal Liver Kinase -1/Flk-1). While the VEGFR-2-transduced angiogenic signals, pathways, and functions are well characterized, the VEGFR-1-mediated functions are poorly understood. The angiogenic functions of placental growth factor (PlGF), which is a specific VEGFR-1-binding ligand, remain controversial. The role of VEGF-B in tumor angiogenesis is still unclear. In addition, the two other VEGF family members, VEGF-C and VEGF-D are the major lymphangiogenic factors that contribute to lymphatic metastasis.

The work contained in this thesis aimed to study the role of VEGF family members in angiogenesis, tumor growth and metastasis. Our work shows that PlGF exhibits a duality in modulation of angiogenesis and tumor growth in a VEGF-A-dependent manner. This is noted when the tumor cell-derived PlGF sensitizes the tumor to the anti-angiogenic and anti-tumor effects of anti-VEGF drugs. We also noted that anti-VEGF treatment induces various vascular alterations in mouse healthy tissues. Additionally, we revealed the collaborative interaction between FGF-2 and VEGF-C in promotion of lymphangiogenesis and metastasis.

In paper I, using two independent tumor models, we show that PlGF modulated tumor growth, angiogenesis, and vascular remodeling through a VEGF-dependent mechanism in either a positive or a negative manner. In the VEGF-A positive model, PlGF inhibited tumor growth and angiogenesis, leading to normalized tumor vasculature with dilated vessel lumens, infrequent vascular branches and increased perivascular cell coverage. Surprisingly, in the VEGF-A negative model, overexpression of PlGF resulted in the opposite phenotype to that seen in the VEGF-A positive model, namely accelerated tumor growth rates and abundant chaotic tumor vessels. Our data uncovered the molecular mechanisms underlying the complex interplay between PlGF and VEGF-A. These findings have conceptual implications for anti-angiogenic cancer therapy.

In paper II, we show that tumors from humans and mice with high levels of expression of PlGF were hypersensitive to anti-VEGF-A and anti-VEGFR-2 therapies. We then validated this finding with a loss-of-function experiment using *PLGF* shRNA in a human choriocarcinoma cell line. Down-regulation of PlGF significantly accelerated tumor growth rate and led to resistance to anti-VEGF drugs. We also show that VEGFR-2 and VEGFR-1 neutralizing antibodies displayed opposing effects on tumor growth and angiogenesis. These findings demonstrate that tumor-derived PlGF negatively modulates tumor angiogenesis and sensitizes treatment effect of anti-VEGF drugs in VEGF-A positive tumors, PlGF level in VEGF-A positive tumor may potentially be a predictive marker of anti-VEGF cancer therapy.

In paper III, we investigated vascular alteration in various organs after systemic treatment with anti-VEGF-A, anti-VEGFR-1 and anti-VEGFR-2 neutralizing antibodies. This study provides functional and structural mechanisms for anti-VEGF drug-induced adverse effects in patients.

In paper IV, we looked into the role of fibroblast growth factor-2 (FGF-2) and VEGF-C on angiogenesis, lymphangiogenesis and tumor metastasis. The results showed that FGF-2 and VEGF-C could both separately and collaboratively promote angiogenesis and lymphangiogenesis in the cornea of the mouse and in the mouse tumor tissue, resulting in pulmonary and lymph node metastases in animal models. By blocking VEGFR-3 and FGF receptor-1 (FGFR-1), we also revealed the fact that VEGFR-3-induced lymphatic endothelial cell (LEC) tip formation is a necessity for FGF-2-FGFR-1 signaling stimulated lymphangiogenesis. This study suggests that combined targeting of FGF-2 and VEGF-C might be an effective approach for cancer therapy and prevention of metastasis.

LIST OF SCIENTIFIC PAPERS

- I. **Xiaojuan Yang**, Yin Zhang, Yunlong Yang, Sharon Lim, Ziquan Cao, Janusz Rak, Yihai Cao. Vascular endothelial growth factor-dependent spatiotemporal dual roles of placental growth factor in modulation of angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13932-7
- II. Eva-Maria Eleonora Hedlund, **Xiaojuan Yang**, Yin Zhang, Yunlong Yang, Masabumi Shibuya, Weide Zhong, Baocun Sun, Yizhi Liu, Kayoko Hosaka, Yihai Cao. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs. Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):654-9.
- III. Yunlong Yang*, Yin Zhang*, Ziquan Cao*, Hong Ji, **Xiaojuan Yang**, Hideki Iwamoto, Eric Wahlberg, Toste Länne, Baocun Sun, Yihai Cao. Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues. Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12018-23
- IV. Renhai Cao*, Hong Ji*, Ninghan Feng, Yin Zhang, **Xiaojuan Yang**, Patrik Andersson, Yuping Sun, Katerina Tritsarlis, Anker Jon Hansend, Steen Dissing, Yihai Cao. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15894-9

* Co-first author

LIST OF RELATED SCIENTIFIC PAPERS

- I. Hosaka K, Yang Yunlong, Seki Takahiro, Nakamura Masaki, Andersson Patrik, Rouhi Pegah, **Yang Xiaojuan**, Jensen Lasse, Lim Sharon, Feng Ninghan, Xue Yuan, Li Xuri, Larsson Ola, Ohhashi Toshio, Cao Yihai. Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. *Nat Commun.* 2013;4:2129.
- II. Ji Hong*, Cao Renhai*, Yang Yunlong*, Zhang Yin, Iwamoto Hideki, Lim Sharon, Nakamura Masaki, Andersson Patrik, Wang Jian, Sun Yuping, Dissing Steen, He Xia, **Yang Xiaojuan**, Cao Yihai. TNFR1 mediates TNF- α -induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. *Nat Commun.* 2014 Sep 17;5:4944.
- III. Lim Sharon*, Honek Jennifer*, Xue Yuan, Seki Takahiro, Cao Ziquan, Andersson Patrik, **Yang Xiaojuan**, Hosaka Kayoko, Cao Yihai. Cold-induced activation of brown adipose tissue and adipose angiogenesis in mice. *Nat Protoc.* 2012 Mar 1;7(3):606-15.
- IV. **Xiaojuan Yang**, Yin Zhang, Kayoko Hosaka, Patrik Andersson, Jian Wang, Ziquan Cao, Yunlong Yang, Hideki Iwamoto, Sharon Lim, Yihai Cao. Vascular endothelial growth factor-B promotes cancer metastasis through a vascular endothelial growth factor-A-independent mechanism of vascular remodeling.
Submitted manuscript

* Co-first author

CONTENTS

1	INTRODUCTION	1
1.1	Tumor angiogenesis.....	1
1.1.1	Functions and architecture of vessels	1
1.1.2	Angiogenesis	2
1.1.3	Tumor vessels.....	3
1.1.4	Angiogenic stimulators	4
1.2	VEGF family in tumor development.....	6
1.2.1	Introduction of VEGF family	6
1.2.2	VEGF-A	6
1.2.3	VEGF-B	8
1.2.4	VEGF-C and VEGF-D.....	8
1.2.5	PlGF	9
1.2.6	VEGFR-1	9
1.2.7	VEGFR-2	9
1.2.8	VEGFR-3	10
1.3	Anti-VEGF cancer therapy.....	10
1.3.1	Neutralizing antibodies	10
1.3.2	Soluble receptors.....	11
2	AIMS.....	13
3	METHODS	15
3.1	Animal model	15
3.1.1	Murine tumor xenograft model.....	15
3.1.2	Metastasis assay	16
3.1.3	Mouse corneal model.....	16
3.2	Experimental methods <i>in vitro</i>	17
3.2.1	Cell proliferation assay	17
3.2.2	Cell migration assay.....	17
3.3	Imaging analysis	17
3.3.1	Labeling of targets	18
3.3.2	Imaging.....	19
4	RESULTS AND DISCUSSION.....	21
4.1	PlGF regulates the tumor vasculature as either a pro-angiogenic or an anti-angiogenic factor depending on its heterodimerization with VEGF-A (Paper I).....	21
4.2	The response to anti-VEGF therapy depends on the level of PlGF in the tumor (Paper II).....	23
4.3	VEGF-dependent plasticity of vasculature in healthy tissue (Paper III).....	25
4.4	FGF-2 promotes lymphangiogenesis and tumor metastasis via VEGFR-3 induced LEC sprouting (Paper IV)	27
5	CONCLUSION AND PROSPECTIVE	31
5.1	Dual roles of PlGF on tumor angiogenesis.....	31

5.2	Signaling modulation by cross communication between proteins	31
5.3	Targeting treatment.....	32
5.4	Combined treatment of malignant cancer	32
5.5	Biomarkers for treatment outcomes and prognosis	33
5.6	VEGFR-3 plays the crucial role in lymphangiogenesis.....	34
5.7	Animal models in preclinical studies	34
6	Acknowledgements.....	35
7	References	39

LIST OF ABBREVIATIONS

AKT or PKB	Protein Kinase B, also known as AKT
Ang	Angiopoietin
CAFs	Carcinoma-Associated Fibroblasts
CCBE1	Collagen and Calcium Binding EGF Domain-containing protein 1
CTCs	Circulating Tumor Cells
CTX	Cyclophosphamide
Dll4	Delta-like 4
DNA	Deoxyribonucleic Acid
ECM	Extracellular Matrix
ECs	Endothelial Cells
EGFR	Epidermal Growth Factor Receptor
ELISA	Enzyme-Linked Immunosorbent Assay
EMT	Epithelial-Mesenchymal Transition
ERK	Extracellular-Signal-Regulated Kinases
Fab domain	Fragment Antigen-Binding domain
FACS	Fluorescence-Activated Cell Sorting
Fc region	Fragment Crystallizable region
FDA	Food and Drug Administration
FGF	Fibroblast Growth Factor
FIGF	C-fos-Induced Growth Factor
Flk	Fetal Liver Kinase
Flt	FMS-Related Tyrosine Kinase
H&E staining	Hematoxylin and Eosin Staining
HGF	Hepatocyte Growth Factor
HIF	Hypoxia Inducible Factor
IFP	Interstitial Fluid Pressure
IGF	Insulin-Like Growth Factor
KDR	Kinase Insert Domain Receptor
LECs	Lymphatic Endothelial Cells
LLC	Lewis lung carcinoma

LRD	Lysine-Fixable Rhodamine Labeled Dextran
LYVE-1	Lymphatic Vessel Endothelial Hyaluronan Receptor-1
MAPK	Mitogen-Activated Protein Kinases
mCRC	Metastatic Colorectal Cancer
MMP	Matrix Metalloproteinase
NG2	Neuron-Glial Antigen 2
NRP	Neuropilin
PAI-1	Plasminogen Activator Inhibitor-1
PCR	Polymerase Chain Reaction
PDGF	Platelet-Derived Growth Factor
PIGF	Placental Growth Factor
Prox-1	Prospero Homeobox Protein 1
RNA	Ribonucleic Acid
shRNA	Small Hairpin RNA or Short Hairpin RNA
SMA	Smooth Muscle Actin
SMCs	Smooth Muscle Cells
sVEGFR	Soluble Vascular Endothelial Growth Factor Receptor
TAMs	Tumor-Associated Macrophages
TEM	Transmission Electron Microscope
TEM1	Tumor Endothelial Marker 1
TGF	Transforming Growth Factor
TIE	Tyrosine Kinases with Immunoglobulin-like and EGF-like Domains
TKIs	Tyrosine Kinase Inhibitors
TNF	Tumor Necrosis Factor
tPA	Tissue Plasminogen Activator
TSPs	Thrombospondins
uPA	Urokinase-type Plasminogen Activator
VEGF	Vascular Endothelial Growth Factor
VEGFR	Vascular Endothelial Growth Factor Receptor
VPF	Vascular Permeability Factor

1 INTRODUCTION

1.1 TUMOR ANGIOGENESIS

1.1.1 Functions and architecture of vessels

In all vertebrates, vessels, including blood vessels and lymphatic vessels, comprise a transportation network for plasma, blood cells, oxygen, nutrition and metabolites throughout the whole body, which is essential for normal physiological functions and has implications in various pathological states¹. The lymphatic vasculature is also involved in tissue fluid homeostasis, the absorption of dietary fat, and the functioning of the immune system².

Blood vessels are divided into three major types according to their function and structure: the arteries are responsible for carrying the oxygenated blood away from the heart; the veins return blood from the capillaries back to the heart and the capillaries are the smallest unit of blood vessels and are the sites of substance exchange between the blood and tissues³.

Lymphatic vessels consist of two types of networks—the initial lymphatic capillaries that specialize in collection of the lymph from the interstitial fluid, and the larger lymph vessels that is responsible for the drainage of the lymph^{3,4}.

There are recognizable structural differences between typical blood capillaries and lymphatic capillaries. The endothelial cells (ECs) of blood vessels are connected with each other by tight junctions and are entirely covered by basement membrane together with contractive mural cells—pericytes and smooth muscle cells. Inversely, the lymphatic vessels start as small blind-ends, have no basal lamina, and the ECs are anchored to the adjacent matrix, which results in the vessels being open to the interstitial space⁵. When the interstitial fluid pressure (IFP) rises, while the blood capillaries may collapse, the lymphatic vessels open, allowing more interstitial fluid to return to the lymphatic system^{2,4,5}.

ECs are the indispensable component of all vessels as they line the interior surface of the vessels and depart the fluid phase from the tissues. The ECs located in different organs participate in various bioactivities, for example, hemostasis, coagulation (thrombosis and fibrinolysis), fluid filtration, arteriosclerosis blood vessel tone, inflammatory recruitment and infiltration, hormone trafficking, and most importantly, they play a very important role in angiogenesis by migration, proliferation and secretion of certain angiogenic factors^{6,7,8}.

The mural cells are another basal structure of the vessel wall. Pericytes are the mural cells of capillaries and venules; smooth muscle cells are the mural cells of other blood vessels. Beneath the ECs, the pericytes line the interior of the basal membrane, and discontinuously cover the vessel wall. They communicate with the ECs by paracrine signaling or direct cell junction, and strengthening the barrier between capillary wall and surrounding tissues^{9,10,11}. Gap junctions between pericytes and ECs allow the exchange of ions and small molecules. Interestingly, cell-cell contact appears necessary for vessel formation and maintenance^{12,13}. The second class of mural cells, smooth muscle cells (SMAs), which are usually located

exterior of the basal membrane, control the vasoconstriction and vasodilation together with pericytes¹⁴.

As a part of tumor microenvironment, the properties of capillaries in tumor tissue contribute to every stage of tumor progression and metastasis¹⁵.

1.1.2 Angiogenesis

More than 220 years ago, the Scottish surgeon Dr. John Hunter first proposed that there is an equilibrium between vascularity and metabolic needs in both healthy and diseased states, which means that the vasculature changes along with the physiological and pathological status of the human body¹⁶. This concept was revisited in 1971 by Dr. Judah Folkman who stated the study of angiogenesis by hypothesizing that tumor growth is angiogenesis-dependent and describing interactions between ECs and tumor cells via tumor-angiogenesis factor¹⁷. From then on, the field of angiogenesis research was established and studied by more and more scientists from all medical and biological fields.

Throughout life, there are two ways of blood vessel formation—“vasculogenesis” and “angiogenesis”¹⁸. Vasculogenesis indicates new vessel formations when there are no pre-existing vessels, whereas, angiogenesis refers to the process of new vessels sprouting from pre-existing vessels^{19, 20}. Vasculogenesis and angiogenesis are indispensable in embryonic development, tissue regeneration, and the female reproductive system, for example, during the menstrual cycle and development of corpus luteum. It also contributes to many pathological disorders, such as cancer, age-related macular degeneration, obesity, asthma, and arthritis^{7, 10, 21, 22}.

Until now, four different bio-mechanisms of angiogenesis have been defined and all of these can be found in tumor development: sprouting, intussusception, mimicry and cooption.

1.1.2.1 Sprouting

Sprouting angiogenesis includes the oriented filopodia extension of the tip cells and proliferation of the stalk cells induced by certain angiogenic factors including vascular endothelial growth factor-A (VEGF-A), angiopoietin-1 (Ang-1), fibroblast growth factor (FGF-2), delta-like 4 (Dll4)^{23, 24, 25, 26, 27} (See 1.1.4). Gerhardt et al. observed that the retina vessel sprouting is controlled by agonistic activity of VEGF-A whereby the tip cells migration is correlated with an increased concentration of VEGF-A, and in the meantime, the stalk cells proliferate upon reaching a concentration threshold of VEGF-A²³.

1.1.2.2 Intussusception

Intussusceptive angiogenesis, also called vascular splitting denotes vascular network formation by protrusion of interstitial tissue columns (tissue pillars or posts) into the vascular lumens, and further transluminal pillars are formed, resulting in new vessel lumens formation^{28, 29}. Intussusceptive angiogenesis not only depends on angiogenic growth factors³⁰,

^{31, 32, 33} but is also regulated by intravascular blood-flow patterns or intravascular shear stress which is a potent trigger of intussusception³⁴.

1.1.2.3 Mimicry

Vascular mimicry describes how highly aggressive tumor cells organize or mimic the vessel-like structure with basal membrane and extracellular matrix (ECM) but without presence of ECs and mural cells³⁵. Vascular mimicry has been observed in several tumor types, and was initially found in malignant melanoma by Dr. Hendrix³⁶, followed by its discovery in breast cancer by Dr. Wakasugi³⁷. Vascular mimicry reminds us that aggressive tumor cells exhibit high plasticity and pluripotency, and mimicry is strongly associated with poor prognosis³⁸.

1.1.2.4 Cooption

Holash et al. first defined vessel cooption when they found that tumor cells migrated toward host blood vessels in well-vascularized organs or in a metastatic site to support blood vessel-dependent tumor growth instead of triggering angiogenesis. These vessels then regress because of apoptosis mediated by Ang-2 expressed by the coopted ECs. Later on, angiogenesis began at the periphery of the growing tumor mass³⁹. Vessel cooption happens during the early stage of tumor development and is dependent on the site of the tumor, often in the brain and lung^{40, 41}.

1.1.2.5 Vasculogenesis

Vasculogenesis is the mechanism by which mesoderm-derived angioblasts (endothelial precursor cells) migrate and differentiate into ECs to form primitive blood vessels. Vasculogenesis mainly occurs during embryonic development of the cardiovascular system and some researchers also found it in adult pathological conditions, for example during hemangioma formation⁴².

1.1.2.6 Lymphangiogenesis

The cellular processes of lymphangiogenesis are considered to be similar to that of hematoangiogenesis—the lymphatic vessels inside or surrounding the tumor mass undergo sprouting and enlargement contributed by migration and proliferation of lymphatic endothelial cells (LECs). These patterns of lymphatic remodeling have been found in various primary human cancers⁴³. Studies on tumor lymphatic vessels mainly focus on the ability of lymphatic capillaries to facilitate the entry and transport of tumor cells^{5, 43, 44, 45, 46, 47}.

1.1.3 Tumor vessels

Angiogenesis is a prerequisite for the process of solid tumor growth and metastasis. When the tumor size reaches to several millimeters in diameter, the tumor will be deprived of oxygen and nutrition since molecules cannot reach to the center of tumor by diffusion. The hypoxic environment in the tumor will trigger tumor angiogenesis. However, compared to healthy tissue, tumor vessels have numerous special properties that may facilitate cancer progression and tumor cell intravasation, as well as the development of resistance to anti-angiogenic

treatment^{21, 48, 49}. ECs, pericytes, and the vascular basement membrane in tumor vessels are all structurally and functionally abnormal, which causes problems when it comes to identification of the tumor vessels^{50, 51}. Structurally, tumor vessels do not have a typical arteriole–capillary–venule hierarchy that is seen in normal tissue. Instead, abundant endothelial sprouting branches are widespread, and some ECs are partially detached or form incomplete layers^{50, 52}. Tumor blood vessels are often irregular, chaotic, tortuous, lack of mural cell coverage and have a relatively higher density compared to normal vasculature. Pericytes of tumor vessels associate with ECs loosely and can even detach from the ECs⁵³. Functionally, tumor vessels are poorly perfused and with greater leakiness, some ECs just sprout in a haphazard manner or form a vessel lumen without blood flow. Conversely, some routes of blood flow are not lined by ECs. These features of tumor vessels endow the tumor microenvironment with high IFP and hypoxic level^{17, 54, 55}.

1.1.4 Angiogenic stimulators

Angiogenesis depends a complex set of cellular events, including proliferation, sprouting, migration and tube formation. The series of cellular events in hematoangiogenesis and lymphangiogenesis may be similar and some blood vessel regulators are involved in lymphatic development as well. In this section, I will briefly introduce several principal pro-angiogenic factors and their roles in tumor angiogenesis, excluding VEGF family members.

1.1.4.1 Fibroblast growth factor-2 (FGF-2)

FGF-2 is a heparin-binding protein that was shown to be a potent pro-angiogenic factor⁵⁶. It promotes neovascularization by stimulating proliferation and migration of ECs, as well as degradation of the ECM through up-regulation of proteases, e.g. matrix metalloproteases (MMPs) and urokinase-type plasminogen activator (uPA)^{57, 58}. FGF-2 is highly expressed by ECs, infiltrated inflammatory cells and various tumor cells, such as prostatic cancers, hematological malignancies, melanoma and pancreatic tumors^{56, 59, 60, 61, 62}. This indicates that FGF-2 may act on all these components via autocrine or paracrine signaling. Under these conditions, FGF-2 may facilitate cancer progression not only by promoting angiogenesis but also by acting directly on tumor cells and tumor-associated macrophages^{62, 63, 64}.

FGF-2 was also shown to be a very strong lymphangiogenic factor through activations of FGF receptor-1 (FGFR-1) and FGFR-3. It has been shown that FGF-2 can also stimulate lymphangiogenesis through up-regulation of VEGF-C^{65, 66, 67}.

In paper IV, we uncovered the mechanism that lymphangiogenic factors, VEGF-C and FGF-2, collaboratively stimulate lymphangiogenesis via VEGF receptor-3 (VEGFR-3) and FGFR-1 transduced signaling pathways.

1.1.4.2 Platelet-derived growth factor-BB (PDGF-BB)

The role of PDGF-BB and PDGF receptor- β (PDGFR- β) in angiogenesis is to promote recruitment, migration and proliferation of mural cells^{68, 69, 70}. In one of our published works,

in addition to abundant PDGF-BB stimulated angiogenesis, we surprisingly found bidirectional modulation of pericytes recruitment to the tumor vessel by PDGF-BB. Tumor cell-derived PDGF-BB detached the pericytes from ECs, whereas, ECs attracted the pericytes by producing PDGF-BB⁷¹.

Additionally, PDGF-BB induced LECs proliferation via activation of mitogen-activated protein kinases (MAPK) as well as enhancing cell motility, thus resulting in intratumor lymphangiogenesis and lymph node metastasis in a mouse tumor model⁷². Later, a clinical study demonstrated that PDGF-BB expression level correlated with lymphatic invasion of human esophageal carcinoma⁷². Recently, prospero homeobox protein 1 (Prox-1) was found to be the responsible transcription factor for maintenance of PDGFR- β ⁷³.

1.1.4.3 Neuropilins (NRPs)

NRPs were originally isolated from the nervous system of *Xenopus*⁷⁴. They are the major receptors of class 3 semaphorins, which play a critical role in several physiological processes including acting as anti-angiogenic factors^{75, 76}. They also participate in angiogenesis as co-receptor of the VEGF family. It has been shown that, VEGF-B and placental growth factor (PIGF) binds to NRP-1, and VEGF-A, VEGF-C as well as VEGF-D can bind to both NRP-1 and NRP-2⁷⁷. NRP-1 is considered critical for vascular formation since *Nrp1*^{-/-} transgenic mice die *in utero* at E13.5 due to severe angiogenic defects⁷⁸.

NRP-2, modulates the VEGF-C signaling pathways as a co-receptor of VEGFR-3⁷⁹. Genetic deletion or antibody neutralization of NRP-2 can block VEGF-C induced lymphatic vessel sprouting *in vivo*⁸⁰.

Moreover, there are some other angiogenic factors binding to NRPs, such as PDGF-BB and FGF-2^{81, 82}.

1.1.4.4 Angiopoietins (Angs)

To date, four isoforms of Ang have been identified and all of them bind to tyrosine kinases with immunoglobulin-like and EGF-like domains 1 (TIE-1) and TIE-2 receptors³⁹. The Angs and TIE receptors are essential to development and maturation of the vascular system. Knockout of any one amongst Ang-1, Ang-2, TIE-1 and TIE-2 are embryonic lethal or result in early postnatal death due to impaired vessel formation^{83, 84, 85, 86}. TIE receptors are mainly expressed on ECs, however, they can be detected on myocardium and on hematopoietic stem cells^{87, 88}. During angiogenesis, Angs-TIEs axes are responsible for vessel formation and stabilization through a complicated equilibrium among all members: Ang-1 strongly activates TIE-2 signal transduction, while Ang-2 acts as an antagonist of Ang-1, however, Ang-2 has very weak stimulatory effect on TIE-2 compared to Ang-1. In addition, TIE-1 may regulate function of TIE-2 by forming heterodimers with TIE-2^{89, 10, 84}.

Lymphangiogenesis is stimulated by Ang-1 via both direct and indirect mechanisms: Direct mechanism is due to activation of TIE-2 expressed on LECs, and indirect stimulation is due

to up-regulated VEGFR-3 expression⁹⁰. Interestingly, one knockout and rescue experiment indicated that Ang-2, considered as an antagonist of TIE-2 during angiogenesis, actually acts as an agonist in lymphangiogenesis⁸⁵.

1.2 VEGF FAMILY IN TUMOR DEVELOPMENT

Among all the pro-angiogenic factors, VEGF family members play the central roles in tumor angiogenesis. In this section, I will discuss more about the VEGF family, the ligands, the receptors, their structures, the signaling transductions, the biological function and especially how they affect tumor angiogenesis and contribute to tumor growth and metastasis.

VEGF-A is the major representative of the VEGF family, usually in the literatures, “VEGF” points to both “VEGF family” and “VEGF-A”. To avoid confusion upon the terms, in this thesis, the “VEGF” only refers to “VEGF family” but not “VEGF-A”.

1.2.1 Introduction of VEGF family

Up to date, in total 7 members of the VEGF family have been identified, including five ligands from the mammalian genome: VEGF-A, VEGF-B, VEGF-C, VEGF-D and PlGF, one analogue ligand from Orf virus—VEGF-E (Orf-VEGF)⁹¹, and one analogue from *Trimeresurus flavoviridis*—T. f. svVEGFs (VEGF-Fs)⁹². In this thesis, I will focus on the five factors coded by mammalian genes, which are all crucial during embryonic development. The genesis of new blood vessels and lymphatic vessels is controlled by these ligands activating three tyrosine kinase receptors—VEGFR-1, VEGFR-2 and VEGFR-3.

According to their receptor binding pattern and functions, we classified these five VEGF family members into three subgroups. PlGF and VEGF-B belong to subgroup as they bind exclusively to VEGFR-1. Generally, VEGFR-1 is widely expressed on blood ECs but not found on the LECs. The second subgroup consisting of VEGF-A, binds to both VEGFR-1 and VEGFR-2, VEGFR-2 is expressed mainly on blood ECs but weakly on LECs of collecting lymphatic vessels. The last subgroup includes VEGF-C and VEGF-D, both of which can activate principally VEGFR-3 as well as VEGFR-2. VEGFR-3, as a marker of LECs and is the main lymphangiogenesis related receptor that is structurally different from VEGFR-2 and VEGFR-1^{93, 94, 95}.

As typical tyrosine kinase receptors, activation of VEGFRs requires ligand dimer to bind to and dimerize two adjacent VEGFR monomers, leading to phosphorylation of tyrosine residues in the intracellular tyrosine kinase domain. This phosphorylation leads to the formation of a binding site for specific proteins, further initiating the signal transduction cascade⁹⁶.

1.2.2 VEGF-A

VEGF-A (formerly known as vascular permeability factor/VPF) was identified separately by Senger et al. in 1983 and Ferrara et al. in 1989^{97, 98}. It is a glycoprotein capable of undergoing dimerization forming two subunits which are connected by disulfide bonds. The human

VEGFA gene expresses several different isoforms of VEGF-A: VEGF-A121, VEGF-A145, VEGF-A165, VEGF-A189, and VEGF-A206. The highly homologous rodent VEGF-A proteins lack one amino acid compared to the human orthologs⁹⁹. Owing to various splice variants of the heparin-binding domain, different VEGF-A isoforms have different levels of solubility. For example, among three major isoforms, VEGF-A121 is completely soluble, VEGF165 is moderately soluble, but VEGF-A189 is almost insoluble¹⁰⁰. The most important isoform *in vivo* is the VEGF-A165, which is expressed in a variety of cells in the body. Isoform-specific mutant mice bearing either VEGF-A120 or VEGF-A188, but not VEGF-A164, were embryonic lethal due to severe defective vessel development, indicating that the isoform VEGF-A164 is essential and sufficient for the normal development of the circulatory system^{101, 102}. Additionally, VEGF-A164 binds to NRP-1 that is a co-receptor for the collapsin/semaphorin family mediating neuronal cell guidance^{103, 104}. VEGF-A is essential for embryonic and early postnatal development. The single allele knockout of *Vegfa* leads to embryonic lethality^{105, 106}.

VEGF-A is the main stimulator of angiogenesis. As a strong mitogen of ECs, it controls proliferation, survival, and migration of the ECs by activating VEGFR-2 and VEGFR-1. VEGF-A can be secreted by tumor cells as well as normal tissue cells, and diffuses to the surrounding area, eventually binding to VEGFRs on the ECs¹⁰⁷. Abundant vessels prompted by VEGF-A alone are tortuous and leaky just like the typical tumor vessels described in section 1.1.3.

It is still controversial when it comes to the lymphangiogenic effect of VEGF-A. Kubo et al. showed in their experiments that VEGF-A could only induce blood angiogenesis not lymphangiogenesis using a mouse cornea assay. However, Dr. Hirakawa detected VEGFR-2 level tumor-associated lymphatic vessels, under his experimental conditions, VEGF-A promoted proliferation of LECs, resulting in tumor metastasis to the sentinel and distant lymph nodes^{65, 108}.

VEGF-A significantly increases vascular permeability through the activation of VEGFR-2¹⁰⁹. Some studies also revealed that VEGF-A has immunosuppressive properties, e.g. induces the accumulation of immature dendritic cells¹¹⁰. Additionally, VEGF-A is involved in hemodynamics by controlling the vasoconstriction and vasodilation^{111, 112}.

It is well known that the tumor possesses a hypoxic core with nearby necrotic when the tumor grows to a critical size. Hypoxia is a very potent stimulator of hundreds of genes, and it is central to the induction of VEGF-A. On one hand, hypoxia can stabilize hypoxia inducible factor 1- α (HIF1- α) and HIF2- α which bind to HIF hypoxia-responsive element of the *Vegfa* promoter, inducing the transcription of DNA. In addition to direct transcription, hypoxia can also lead to the stabilization of VEGF-A mRNA¹¹³. Thereafter, VEGF-A can be secreted by various hypoxic cells, and diffuse to the surrounding zone, to promote new vessel formation and relieve the tissue from hypoxia^{107, 113, 114}.

1.2.3 VEGF-B

VEGF-B was first isolated in 1996, and two isoforms were identified, VEGF-B186 and VEGF-B167¹¹⁵. Both VEGF-B isoforms bind to VEGFR-1 and the co-receptor—NRP-1. The isoform VEGF-B167 possesses the heparin-binding domain, whereas VEGF-B186 does not contain the heparin-binding domain^{116, 117}. *Vegfb*^{-/-} mice developed normally except for minor defects during cardiovascular formation and revascularization^{118, 119}.

Studies on the role of VEGF-B in angiogenesis mainly focus on heart and brain tissue revascularization. When it comes to tumor vessel angiogenesis, limited research has been conducted. It is reported that VEGF-B increased the mRNA level of uPA and Plasminogen activator inhibitor-1 (PAI-1), but not tissue plasminogen activator (tPA) activity in certain ECs *in vitro*¹¹⁶, however, VEGF-B did not show pro-angiogenic activity in our tumor bearing mice model and many other studies *in vivo*¹²⁰. More and more clinical studies show that the VEGF-B levels in tumor tissue correlated with tumor progression and a worse prognosis^{121, 122, 123, 124}. Recently, a study on biological activities of VEGFR-1 demonstrated that, unlike PlGF, VEGF-B may not efficiently induce downstream signaling of VEGFR-1¹²⁵. whereas, it has been shown that VEGF-B is able to form heterodimers with VEGF-A *in vitro*, thus VEGF-B may be able to regulate the activity of VEGF-A¹²⁶.

1.2.4 VEGF-C and VEGF-D

In the VEGF family, there are two members that has been shown experimentally to contribute to lymphangiogenesis—VEGF-C and VEGF-D. These are the most well-known lymphangiogenic stimulators that activate VEGFR-2 and VEGFR-3. Activation of VEGFR-3 stimulates protein kinase C-dependent activation of the extracellular-signal-regulated kinase 1 (ERK1) or ERK2 signaling cascade and phosphorylation of protein kinase B (PKB, also known as AKT), leading to survival, proliferation and migration of LECs^{39, 40, 127}, as well as lymphatic smooth muscle cells alteration at the collecting lymphatic vessels¹²⁸.

People used to think that lymphatic capillaries cannot grow into the tumor due to their thin and are structurally weak. Several studies showed that VEGF-C and VEGF-D promoted lymphatic metastasis by inducing intratumoral and peripheral lymphatic vessels growth via binding to VEGFR-3^{129, 130, 131}.

Joukov et al. isolated *VEGFC* cDNA from prostatic cancer and determined that VEGF-C binds to tyrosine kinase receptor VEGFR-3 and VEGFR-2^{132, 133}. The homozygous *Vegfc* knockout mice aborted between E15.5 and E17.5 due to severe swelling caused by the absence of lymphatics, and whilst the heterozygous can survive, they show hypoplasia of cutaneous lymphatics¹²⁷.

VEGF-D was initially termed the c-fos-induced growth factor (FIGF) when it was isolated for the first time, and was found to be a mitogenic factor for fibroblasts¹³⁴. VEGF-D has a very similar protein structure to VEGF-C and has been shown to bind to the same receptors.

Due to these similarities, in a zebrafish model, *Vegfd* could rescue loss of *Vegfc* and compensate for its function in lymphatic sprouting¹³⁵.

1.2.5 PIGF

PlGF exclusively binds to VEGFR-1. As the name suggests, PlGF is mainly expressed in the placenta, however, it is also detectable in the heart, lung and skeletal muscle at lower levels. The gene for PlGF in humans code for four isoforms, they are PlGF-1, PlGF-2, PlGF-3 and PlGF-4, whereas, only PlGF-2 exists in the mouse¹³⁶.

Genetic ablation of PlGF does not affect vessel structure during physiological development¹³⁷ but it dose alter angiogenesis during pathological conditions such as hypoxic brain, myocardial ischemia, and wound healing^{137, 138}. Studies examining the effects of PlGF on tumor angiogenesis and progression were controversial. On one hand, it is demonstrated that PlGF suppressed tumor growth in mouse models of LLC and fibrosarcoma, and led to the dilation of the tumor vessels and inhibited vessel branching¹³⁹. On the other hand, overexpression of PlGF in mouse melanoma increased the tumor growth and pulmonary metastases through activation of MMPs and tumor angiogenesis¹⁴⁰.

Additionally, since VEGFR-1 is involved in recruitment of monocytes and macrophages, thus PlGF may promote angiogenesis indirectly by attracting inflammatory cells that secret pro-angiogenic factors¹⁴¹. It has been reported that PlGF reconstituted hematopoiesis by recruiting VEGFR-1⁺ stem cells from bone marrow.

In paper I, we uncovered the mechanism by which PlGF regulates VEGF-A-VEGFR-2 signaling in both a negative and a positive manner by heterodimerization with VEGF-A and competitive binding to VEGFR-1. In paper II, we demonstrated that PlGF in tumor cells led to sensitization of the tumors to anti-VEGF therapy.

1.2.6 VEGFR-1

The function of VEGFR-1 is uncertain and quite controversial. When both alleles of *Vegfr1* were deleted, the mice embryos showed hyper-proliferation of ECs and are aborted early in development¹⁴². Whereas, if only the tyrosine kinase domain from VEGFR-1 was deleted, the mice developed normally¹⁴³, however, isolated monocytes showed impaired migration *in vitro* under stimulation from VEGF-A and PlGF¹⁴⁴. Downstream signaling pathway of VEGFR-1 is still an enigma until today¹⁴⁵.

1.2.7 VEGFR-2

In contrast to VEGFR-1, the role of VEGFR-2 in angiogenesis is relatively well elucidated. After receptor undergoes dimerization and autophosphorylation of the tyrosine kinase residues on the intracellular domain, it is capable of activating of various pathways, primarily: (1) The phospholipase C (PLC)- γ /protein kinase C (PKC) pathway, leading to the beginning of the c-Raf-MEK-MAPK cascade and cell proliferation. (2) The PI3K-Akt signal

transduction pathway, contributing to cell survival. (3) The p38 MAPK signaling pathway, resulting in cell migration and, (4) eNOS activation for vascular permeability^{109, 146, 147}.

1.2.8 VEGFR-3

VEGFR-3 is the major receptor for VEGF-C and VEGF-D and is essential for the development of the lymphatic vessels. Primitive lymphatic vessels are transdifferentiated from the Prox-1⁺ embryonic veins,¹⁴⁸ the Prox-1⁺ cells undergo differentiation and form the lymphatic vessels when they were exposed to VEGF-C which activates the VEGFR-3 on these cells. The VEGFR-3 is eventually shifted from the embryonic veins to the lymphatic vessels and became a specific marker of lymphatic vessels^{149, 150}. Despite this, VEGFR-3 can also be expressed on blood capillaries in tumor angiogenesis or during wound healing^{151, 152}. Similar to *Vegfc* knockout mice, complete deletion of the *Vegfr3* gene causes early embryonic death due to defective blood vessel development in embryos—the large vessels' lumens develops abnormally, leading to serious edema and cardiovascular failure at E9.5^{153, 154}.

1.3 ANTI-VEGF CANCER THERAPY

Based on Dr. Judah Folkman's hypothesis that all solid tumor growth is dependent on angiogenesis, anti-angiogenic therapy could be considered to be an efficient way of inhibiting tumor growth. The aim of anti-VEGF treatment is to prevent the activation of VEGFR and the downstream signaling pathways, thus hindering the neovascularization in tumor tissue, and eventually resulting in tumor vessel regression and markedly reduced tumor growth.

Some possible ways of inhibiting VEGF signals include: (1) Neutralizing antibodies that block the VEGF family ligands. (2) Neutralizing antibodies that block the VEGFRs, thus obstructing activation of the receptors. (3) Soluble receptors with the ligand-binding domain of membrane receptors, acting as decoy for the ligands before they bind to the receptors on the cell surface. (4) Small molecules that block ligand-binding sites on VEGFRs. (5) Tyrosine kinase inhibitors (TKIs)—small molecules with the ability of crossing the cell membrane that bind to the tyrosine kinase domain of the VEGFRs to inhibit the activation of downstream signaling pathways. (6) RNA interference technology.

1.3.1 Neutralizing antibodies

In the past 20 years, a few non-human antibodies were developed and their efficiency were validated using mice model in preclinical experiments. These heterogenic antibodies may induce the human immune response if they are directly introduced into patients, therefore humanization of the antibodies is required. Usually, the standard way of humanizing an antibody is to transfer the specific binding region to a human antibody framework¹⁵⁵.

Nowadays, anti-VEGF-A antibodies are the most well-developed blockades among the anti-angiogenic treatments since the function of VEGF-A is well understood. Dr. Ferrara made the first anti-VEGF-A antibody called A4.6.1¹⁵⁶. Later, A4.6.1 was humanized into bevacizumab (Avastin, Genentech/Roche) which is the first monoclonal antibody approved to treat malignant cancer. Recently, ranibizumab (Lucentis, Genentech), a smaller neutralizing

antibody containing only the fragment antigen-binding (Fab) domain of IgG was derived from bevacizumab, it has 140 times higher affinity for VEGF-A than bevacizumab¹⁵⁷, but until now, ranibizumab is only approved for macular diseases.

Early this year, a human VEGFR-2 antagonist (ramucirumab) developed by Eli Lilly and Company was approved by the Food and Drug Administration (FDA) for treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine- or platinum-based chemotherapy¹⁵⁸.

1.3.2 Soluble receptors

Regeneron Pharmaceuticals generated a decoy receptor that is a fusion protein of domain 2 from VEGFR-1, domain 3 from VEGFR-2 and an IgG Fc. This VEGF trap blocks not only VEGF-A but also PlGF and VEGF-B¹⁵⁹. It is approved for metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen, and is marketed under the commercial name ZALTRAP¹⁶⁰.

In addition, tumor lymphangiogenesis is clearly associated with the lymphatic metastasis. To block the lymphangiogenesis pathway, soluble VEGFR-3 was developed by fusing the VEGFR-3 domain to an IgG fragment crystallizable (Fc) region. This fusion product inhibited lymphangiogenesis and lymph nodes metastasis in a murine tumor model¹⁶¹ and ablated lymphangiogenesis in embryonic mice¹⁶².

2 AIMS

The overall aim of this thesis was to investigate the role of VEGF family members in tumor angiogenesis, tumor growth, and metastasis.

The specific aims included:

To explore the mechanism of VEGF-A dependent PlGF induced tumor vessel remodeling.

To elucidate the role of PlGF in anti-VEGF drug resistance and sensitivity.

To study the systemic effects of VEGF targeting drugs.

To understand the effects of two lymphangiogenic factors VEGF-C and FGF-2 on lymphangiogenesis and tumor metastasis, and the interplay between VEGF-C and FGF-2.

3 METHODS

In this section, I will highlight the details in the methods used in our research that require extra attention or discussion. The details of each protocol can be found in the constituent papers.

3.1 ANIMAL MODEL

It is difficult to relate conclusions from an animal experiment directly to clinical practice since there are individual variances amongst people as well as many biological differences between animals and humans. Despite not being able to relate the situation seen in animals directly to humans, in most preclinical studies, animal models are necessary. Laboratory animals have identical and homogeneous biological backgrounds, thus it is easier to exclude individual variability from a group of model animals in comparison with a human population, and therefore a smaller sample size is needed for equal statistical power. Additionally, there is better accessibility to a larger sample size when it is required. To manage and collect samples from a group of animals is more feasible. The animal models are also able to take over the majority of risks during scientific research, for example, the toxicity of a new compound or a new therapeutic protocol. These points are important given the *in vitro* experiments can currently not mimic the systemic reaction of a whole organism, or many complex interactions seen in the human body.

3.1.1 Murine tumor xenograft model

To validate the anti-tumor therapeutic protocol, we have to perform animal experiments. In this thesis, we inoculated tumor cells subcutaneously into the mid line dorsal area to be able to observe the tumor size accurately in real-time, meanwhile, to avoid influences from interscapular and inguinal adipose tissue that are highly vascularized organs. If such close observation of the tumor size is unnecessary, the orthotopic tumor model is preferred, because it provides an appropriate tumor microenvironment and produces accurate phenotypes.

We measured the tumor size with vernier calipers. And the volume of tumor was calculated according to a formula: tumor size = length \times width² \times 0.52 if the tumor grew into hemispheric mass. If the tumor was not hemispheric, we compensated by measuring the dissected tumor mass. The dissected tumor mass was obtained for the JE-3 tumor in paper II and the metastatic lymph nodes in paper IV.

When one treats the mice with antibodies or small molecules, one should consider the following issues. Firstly, the best route of drug administration must be decided upon. These can be oral (p.o.), intravenous injection (i.v.), or intraperitoneal injection (i.p.). If possible, we first select the same route of administration as the clinical application of the drug. An example of this would be sunitinib as it is given orally in paper II. Secondly, the pharmacological properties should be taken into consideration, for example when a drug needs to be cleaved into its functional metabolite by low pH, we have to choose p.o. to

transport the drug into stomach. Additionally, we tend to choose the easiest route of administration to minimize suffering of the mice. The second point of consideration is to optimize the dosage. Every species has specific metabolic rates and other features that affect pharmacokinetic parameters, moreover, the sensitivities to the drug also alter in different animals. So one should consider the species, age, gender and size of the animal when one calculates the dosage, and a pilot experiment using different dosages is often required.

Finally, we need to sacrifice the mice using different methods according to the ethical permit and the purpose of the experiment. If we want to collect blood by heart puncture or the mice need to be perfused through heart injection, CO₂ inhalation is the best approach. Otherwise, cervical dislocation is a good way to prevent undue pain during euthanasia.

3.1.2 Metastasis assay

Nowadays, several *in vivo* metastasis models are frequently used to evaluate every steps of distal metastasis. In order to evaluate the capability of tumor cell intravasation, we can check the number of fluorescently labeled circulating tumor cells (CTCs) using Fluorescence-activated cell sorting (FACS) or by blood culture assay⁷¹. If tumor cells were injected via the tail vein, by observation of the formation of metastatic nodules in distal organs, we can obtain information on tumor cell extravasation¹⁶³. In paper IV, we examined the pulmonary metastasis to assess the hematogenous metastasis as the dorsal subcutaneous tumors have the tendency to metastasize to the lung. To evaluate lymphatic metastasis, we examined the subaxillary lymph nodes, as these are the sentinel lymph nodes for our tumor bearing mice model. Recently, we developed a new zebrafish metastasis model with which we can ascertain the aggressiveness of a tumor cell line efficiently¹⁶⁴.

3.1.3 Mouse corneal model

In order to understand the mechanisms behind angiogenesis or examine the capabilities of an angiogenic factor to exert an effect, proper biological assays need to be established. In the past, a series of *in vitro* and *in vivo* assays have been developed and utilized to investigate angiogenesis^{165, 166}. The *in vivo* assays allow us to observe the exact outcomes in a sophisticated physiological tumor microenvironment, which can never be reproduced *in vitro*. Amongst all the *in vitro* assays available, we chose the mouse corneal micropocket assay to study angiogenesis and lymphangiogenesis stimulated by FGF-2 and VEGF-C in paper IV based on the following considerations: (1) Compared with the chick embryo chorioallantoic membrane (CAM) assay and transparent zebrafish embryos, mice have less species difference from human beings. (2) Unlike the fragile CAM, the cornea is naturally exposed to the air and will not be disturbed by the atmospheric gas levels or unregulated pH. (3) The new vessel formation in the cornea is considered to be the most reliable evidence of neo-angiogenesis, because the mouse cornea is a completely avascular tissue and can avoid influence from pre-existing vessels¹⁶⁷. (4) According to our previous data, the mouse corneal micropocket assay is reliable, stable and quantitative.

The stimulators are not placed in the center of the mouse cornea, the new vessels usually grow unevenly. In order to compare the quantified data in a reproducible and equitable way we divided the whole flat-mounted cornea into four circular sectors and named them according to their location relative to the pellets, for example, 1.5-4.5h. After this we can compare the vessel area of the whole cornea from each groups, or the vessel area in the same sector from different groups.

3.2 EXPERIMENTAL METHODS *IN VITRO*

3.2.1 Cell proliferation assay

In paper I, II, and IV, we measured the cell proliferation rate using the MTT assay. The basic rationale of MTT assay is to detect the formazan product from reducing MTT, which is used as an approximation of the amount of MTT taken up by living cells. This is a quick and convenient assay, but is not a suitable way of comparing proliferation rates of different cell types. This is due to variability of different cell types to reduce MTT. Additionally, the value from this assay does not give the exact number of cells in each sample but just provides an impression of the relative cell density. The MTT reagent is sensitive to light, so the MTT assay should be performed in the dark. Nowadays, other tetrazolium salts have been developed to replace MTT, e.g. XTT¹⁶⁸, MTS, WSTs¹⁶⁹.

3.2.2 Cell migration assay

To study the ability of cells to migrate or evaluate chemotactic strength of an attractor on a certain type of cell, target cells and agents were usually assembled into a 3D culture system where the cells can be co-cultured with the other cells or factors. The Boyden chamber assay is one of the classical ways for studying cell chemotaxis—cell motility toward increasing concentrations of soluble attractants. In paper IV, we used the Boyden chamber assay to measure LEC migration, as our purpose was to assess VEGF-C and FGF-2 stimulated cell migration regardless of the effect on cell proliferation and cell-cell interactions. In this chamber, ECs generally go through the porous membrane within a few hours, a much shorter time than is required for cell division. The other well established systems for evaluating of cell migration include the *in vitro* wound healing assay, the tube formation assay, and the cell mobility assay in matrigel^{170, 171}.

3.3 IMAGING ANALYSIS

Imaging is an important method to evaluate neo-angiogenesis. The vasculature can be distinguished from the surrounding tissues by perfusion reagents, specific vessel markers and by cell conformation^{41, 51}. In this thesis, we imaged the vessels with a stereomicroscope (Paper IV), a confocal microscope (all papers) and a transmission electron microscope (TEM, Paper III).

3.3.1 Labeling of targets

In order to detect a certain group of cells to be able to analyze their location, number or morphological features, we label them with specific cell markers. Usually the same marker can be shared by different groups of cells while one cell can express several markers, therefore we may identify the target cells with more than one markers.

3.3.1.1 Blood endothelial markers

CD31 is a widely used immunohistological marker for ECs, therefore it was chosen for this thesis. CD31, also known as platelet endothelial cell adhesion molecule-1 (PECAM-1), is a pan marker for blood ECs. CD31 is not only highly expressed on the surface of adult and embryonic vascular ECs but also expressed on bone marrow stem cells, platelets, megakaryocytes, myeloid cells, T lymphocytes, trophoblasts¹⁷², and even human brown adipocytes¹⁷³. CD34 is also another frequently used EC marker and is mainly expressed on early hematopoietic and vascular-associated tissue. Additionally, endomucin, VEGFR-2, and Dll4 amongst others also serve as endothelial markers in diverse studies^{166,174}.

3.3.1.2 Lymphatic endothelial markers

Various proteins have been used as LEC markers, including VEGFR-3¹⁴⁹, LYVE-1¹⁷⁵, podoplanin¹⁷⁶, Prox-1^{148, 177} and NRP-2⁴. In paper IV, LYVE-1 was used for immunofluorescence staining to distinguish lymphatic vessels from blood vessels in tumors. It is generally expressed on LECs of lymphatic capillaries but not on LECs from collecting lymphatics¹⁷⁵.

3.3.1.3 Mural cell markers

The detection of pericytes is often dependent on certain angiogenic stage of the tissue or in a tissue-specific manner^{12, 13}. Neuron-gial antigen 2 (NG2), also known as melanoma-associated chondroitin sulfate proteoglycan, is the most widely used pericytes surface pan-marker (Paper I and II). Interestingly, NG2 binds to angiogenic regulators such as FGF-2, PDGF-AA and angiostatin¹⁷⁸. As the name suggests, NG2 is expressed in the central nervous system by oligodendroglial precursor cells and pericytes¹⁷⁹. PDGFR- β , also a cell-surface protein, is the critical receptor controlling the recruitment of pericytes. It is expressed in pericytes progenitors and pre-mature pericyte, however in the mature pericytes, PDGFR- β is expressed in lower levels¹⁸⁰. Alpha-smooth muscle actin (α SMA) is widely expressed by the smooth-muscle cell lineage and myofibroblasts (Paper I)¹⁸¹. Similarly, desmin is usually expressed in muscle cells, including skeletal muscle cells, smooth muscle cells and myocardial cells¹⁸². Both Desmin and α SMA are normally used as markers of contractive mural cells. Additionally, by gene expression profiling, new pericyte markers were identified from PDGF-BB deficient embryos¹⁸³. Regulator of G-protein signaling 5 was found in pericytes and smooth muscle cells. Its expression is further induced during angiogenesis. Interestingly, Kir6.1 is considered as another specific pericytes marker, but it is detectable in special tissue, for example, brain and pancreas^{69,183}.

3.3.2 Imaging

In this thesis, several microimaging techniques were used to observe alterations in angiogenesis. In paper IV, under the stereomicroscope, we saw the gross new blood vessel structures but not the lymphatic vessels due to the presence of red blood cells. In paper III, TEM allowed us to see the endothelial fenestrations and caveoli directly without labeling as it was possible to distinguish the capillary ECs according to their special ultrastructure and cellular organelles.

Confocal microscope imaging is a robust technique to acquire 3D reconstructions of the vasculatures. It is also the most frequently used method in our studies. Before scanning, we perform a whole mount staining procedure to label the samples with fluorescein and specific cell markers. Even though whole mount staining requires fresh tissues and consumes more time and reagents, the confocal imaging allows us to: (1) reconstruct the whole 3D structure of the vessels, (2) see the deep layer of the sample, (3) obtain precise positional information of each component of the tissue, (4) observe the details of the cell in a 3D pattern and (5) localize the labeled molecules in the cell^{184, 185}.

4 RESULTS AND DISCUSSION

The constituent papers in this thesis describe the angiogenic effects of VEGF family members on the tumor vasculature (paper I, II and IV), the results from the remodeling of tumor vessels including impacts on distant metastasis (paper IV) and therapeutic outcomes of anti-VEGF treatment (paper II). Finally, paper III illustrated the systemic consequences of anti-VEGF treatment.

4.1 PLGF REGULATES THE TUMOR VASCULATURE AS EITHER A PRO-ANGIOGENIC OR AN ANTI-ANGIOGENIC FACTOR DEPENDING ON ITS HETERODIMERIZATION WITH VEGF-A (PAPER I)

Despite numerous studies, the role of PlGF in tumor growth and angiogenesis is still controversial¹⁸⁶. Up-regulation of PlGF has been reported to be a promoter of mouse melanoma angiogenesis, growth and metastasis¹⁸⁷. However, in another tumor model, overexpression of PlGF showed the opposite effects¹⁸⁸.

Why does this debate exist? Bjorndahl et al. have reported that PlGF and VEGF-A heterodimerize with each other¹⁸⁹. We propose that the different experimental results come from the complicated cross-talk of PlGF, VEGF-A, VEGFR-1 and VEGFR-2.

To simplify the study, we removed the key factor—VEGF-A from this system by choosing a VEGF-A-null tumor cell line as the major subject. This mouse fibrosarcoma tumor cell line, 528ras, was derived from VEGF-A deficient mice embryos, the Ras oncogene was transfected into the non-tumorigenic fibroblasts to give rise to a highly tumorigenic and fibrosarcoma¹⁹⁰. Another mouse fibrosarcoma tumor cell line T241 was used as VEGF-A-positive control.

To investigate the function of PlGF on VEGF-A negative and VEGF-A positive tumors, *PLGF* cDNA was cloned into 528ras and T241 cells to yield overexpression of PlGF. However, the overexpression of PlGF had no impact on tumor cell proliferation rates *in vitro* (Figure 1A). We then checked the levels of various dimers inside and outside the tumor cells by performing a sandwich ELISA assay using cell lysate and cell culture conditioned medium. The ELISA data verified that the PlGF/PlGF dimers were markedly up-regulated in *PLGF* transfected cells and the majority of PlGF homodimers were secreted into the conditioned medium. Despite this, VEGF-A/PlGF heterodimers were significantly increased in the medium of *PLGF* transfected VEGF-A positive cells. Interestingly, the secretion of VEGF-A/VEGF-A homodimers was partially prevented by formation of VEGF-A/PlGF heterodimers (Table S1).

We wondered what would happen in tumor vasculature based on the changes of various dimers detected *in vitro*, so we implanted tumor cells subcutaneously into C57BL/6 mice. Using the s.c. tumor-bearing mouse model, we monitored the tumor development by palpation and measured the tumor size with vernier calipers. Usually, the tumor masses under

the skin grew in a hemispherical manner, the volume of tumor was calculated according to a formula mentioned above.

First, we investigated the angiogenic effect of PIGF in VEGF-A positive tumors. One million T241 Vector or T241 PIGF tumor cells were injected into each mouse. It took 16 days for T241 Vector tumors to grow to 1 cm³. Within the same period, the average volume of T241 PIGF tumors only reached 0.5 cm³ (Figure 1B lower chart). High levels of PIGF suppressed primary tumor development in VEGF-A positive tumor cells.

We then examined the tumor vessel structure using immunohistofluorescent staining with an EC marker—CD31 and a pericyte specific marker—neuron-gial antigen 2 (NG2). Analysis of 3D images of intratumoral vessels showed that the average number of vessels per field dramatically reduced and the vessels were noticeably more dilated in the *PIGF* transfected tumors. Compared with the T241 vector tumor, T241 PIGF tumor vessels were smoother with less branching points. The NG2 signal increased in the *PIGF* transfected tumors, showing they possessed better pericyte coverage (Figure 1C and D).

Besides the vessel structure, we also explored the functional changes that resulted from PIGF-induced tumor vessel remodeling, including perfusion and leakage of vasculature in the tumors. For this purpose, we perfused the tumor bearing mice with two forms of a hydrophilic polysaccharides dextran weighing either 2000 kDa or 70 kDa through the tail vein just before euthanasia of the animals. The dextran was labeled with a fluorescent dye and conjugated to lysine residues that can subsequently be treated with paraformaldehyde for fixation. The dextran perfusion assay showed that improved pericyte coverage in PIGF tumor reduced extravasated 70 kDa dextran, and increased the number of 2000 kDa dextran perfused vessels due to more organized vasculature in PIGF tumor (Figure 1E and F).

To validate the phenomena we saw, especially when these data were inconsistent with results from some previous literature, we established another stable high PIGF expressing cell line, the Lewis lung carcinoma (LLC) PIGF. We saw the same trend of tumor growth and vessel remodeling as in the previous experiment using the T241 PIGF tumors. The growth of high PIGF tumors was slower compared to vector tumor and in high PIGF tumors, the vessels were dilated and the vascular sprouting was suppressed, resulting in less branch points and a greater coverage of pericytes (Figure S1).

Next, we investigated the angiogenic effect of PIGF in VEGF-A negative tumors. The VEGF-A-null tumor cells with or without PIGF overexpression were inoculated subcutaneously into immune deficient SCID mice subcutaneously. The same experimental procedures were performed and the same parameters were checked and recorded as in the T241 tumor cell experiments. Surprisingly, genetic deletion of VEGF-A from the tumor cells completely reversed the PIGF induced inhibition of tumor growth and remodeling of tumor vasculatures. Compared to the vector control tumors, in VEGF-A-null PIGF tumors we firstly saw that tumor growth rate was accelerated by more than 50% (Figure 1B upper panel). Secondly, the number of CD31 positive vessels were tripled and the number of branch points

doubled. Additionally, the α -SMA marked smooth muscle cell coverage was decreased to about 40% (Figure 1C and D). For the vessel function indexes, the extravasated 70 kDa dextran was dramatically increased, which indicated very leaky vessels, while the 2000 kDa perfused vessel number was significantly decreased (Figure 1E and F).

The question remained as Why PlGF played a pro-angiogenic role in this tumor model. Did the PlGF itself change VEGF-A levels in the tumor? The enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR data demonstrated that both protein and mRNA levels of VEGF-A were not altered by overexpression of PlGF in VEGF-A-null tumors (Figure S2C and D). We also examined the tumor-associated macrophages (TAMs) in tumor tissue. Our results differed from another study that showed there was an increase in the switch from M2-like macrophages to M1 macrophages when PlGF was down-regulated¹⁹¹. Our study showed that transfection of PlGF led to a decrease in the number of CD206⁺ M2-like macrophages in VEGF-A-null tumors.

In order to answer whether the angiogenic promotion in the VEGF-A-null PlGF tumor was dependent on host-derived VEGF-A, we blocked VEGF-A with an anti-VEGF-A neutralizing antibody. We administered the anti-VEGF-A neutralizing antibody (also called VEGF blockade in the paper) through intraperitoneal injection, so VEGF-A from all sources should be blocked. As a result, the vessel density of VEGF-A-null PlGF tumors was brought down to the same level as that of VEGF-A-null vector tumor (Figure 2). These data showed that the host-derived VEGF-A was driving factor of angiogenesis in VEGF-A-null PlGF tumors.

Furthermore, we treated the tumor bearing mice with a VEGFR-2 specific neutralizing antibody (DC101, also called VEGFR-2 blockade in the paper) to define the function of VEGFR-2 transduced signaling on PlGF stimulated tumor angiogenesis. Comparable to VEGF-A blockade, anti-VEGFR-2 treatment inhibited tumor growth and vascular sprouting in VEGF-A-null PlGF tumor (Figure 3). This finding verified the critical role of the VEGF-A-VEGFR-2 signaling pathway in tumor angiogenesis. Interestingly, unlike the data from VEGF-A positive tumors, both VEGF-A and VEGFR-2 inhibition did not alter the average vessel diameter in VEGF-A-null tumors (Figure 2 and 3).

4.2 THE RESPONSE TO ANTI-VEGF THERAPY DEPENDS ON THE LEVEL OF PLGF IN THE TUMOR (PAPER II)

The first paper demonstrated that the interaction between VEGF-A and PlGF affected vascular remodeling. In addition to those findings, the anti-VEGF-A and anti-VEGFR-2 treatment outcomes gave an idea that the PlGF high expression tumors still respond to anti-VEGF therapy even without tumor cell-derived VEGF-A.

With the purpose of uncovering the contribution of the complex interplay between VEGF-A and PlGF to the therapeutic efficiency of anti-VEGF treatment, we treated both human and mouse PlGF-expressing tumors with several anti-VEGF agents.

In order to screen for an appropriate human tumor cell line, we performed ELISA assay to measure intrinsic PlGF levels in the conditioned medium of different human tumor cell lines. Among all the studied tumors, JE-3 choriocarcinoma expressed the highest level of PlGF, which is not surprising because JE-3 choriocarcinoma is a trophoblastic cancer from placenta (Table S1). We further looked at the vessel structure in all of these tumor tissues by detecting vascular ECs using an anti-CD31 antibody, as expected, the microvessels in the JE-3 tumors had normal properties compared with other human tumors, namely a very smooth vessel contour line with fewer branching points (Figure S1). We made a JE-3 tumor bearing immune deficient SCID mouse model and treated the mice with different anti-VEGF drugs: the anti-VEGF-A neutralizing antibody, the anti-VEGFR-1 neutralizing antibody (MF1, also called VEGFR-1 blockade in the paper), and the anti-VEGFR-2 neutralizing antibody.

Our data demonstrated that JE-3 tumors are hypersensitive to anti-VEGF-A and anti-VEGFR-2 antibodies treatment, but did not respond to anti-VEGFR-1 treatment. At first, the tumor growth curve showed that anti-VEGF-A and anti-VEGFR-2 antibodies dramatically suppressed tumor growth, while the anti-VEGFR-1 antibody did not change the tumor growth rate (Figure 1A and D). The measurement of tumor weight at the experimental endpoint showed the same trend. When we examined the tumor vasculature under confocal microscope, consistent with the growth curve, fewer vessels or even avascular areas were frequently found in anti-VEGF-A and anti-VEGFR-2 treated tumor. In contrast, VEGFR-1 blockade surprisingly increased the tumor vessel density and endothelial cell sprouting. All anti-VEGF agents also resulted in reduced pericyte coverage on the tumor microvasculatures (Figure 1B and E). These findings validate the observation that PlGF-expressing JE-3 tumors were highly sensitive to VEGFR-2 blockade.

In order to know whether the hypersensitivity of JE-3 tumors to anti-VEGF-A and anti-VEGFR-2 blockades is linked to PlGF, we down-regulated PlGF expression in JE-3 tumor cells by *PLGF*-shRNA transfection. Compared to *PLGF*-shRNA transfected cells, quantitative real time PCR showed that the relative *PLGF* mRNA level dropped to 40% while the *VEGFA* mRNA level remained constant (Figure 2C), as did the cell proliferation rate *in vitro* (Figure S3B).

We then treated the control-shRNA JE-3 and *PLGF*-shRNA tumor bearing mice with VEGFR-2 blockade, and measured the growing tumor size every two days. Under these conditions, we were able to judge the drug sensitivity by calculating efficiency of inhibition, which is presented by T/C value (tumor volume of treated group / tumor volume of control group) at both the endpoint and the same-tumor-size point: the smaller the T/C value is, the more sensitive the tumors are to the drugs. As shown in figure 2, knockdown of PlGF in the JE-3 choriocarcinoma not only accelerated the tumor growth *in vivo*, but also led to acquired drug resistance as determined by a rise in the T/C value.

To further explore the mechanism of PlGF mediated drug sensitivity to anti-VEGF treatment, we established a PlGF-expressing T241 fibrosarcoma cell line, and analyzed various VEGF and PlGF dimers levels in cell culture conditioned medium. As expected, T241 PlGF tumor

cells secreted a large amount of PlGF/PlGF homodimers and VEGF-A/PlGF heterodimers (Table 2). Certainly, as seen previously in our research group, the T241 PlGF tumor grew slower than the vector control tumor. In order to exclude the possibility that PlGF directly slowed down tumor cell proliferation, we also tested tumor cell growth *in vitro* and found no difference between these two groups. Additionally, the VEGFR-1 and VEGFR-2 mRNA levels in tumor cells were also monitored by RT-PCR under the positive control of ECs, but neither were detectable. As an extra control, we stimulated the T241 cells with PlGF and VEGF-A protein *in vitro*, and did not see any difference in the rate of cell proliferation (Figure S3).

The T241 tumor bearing mice were then treated with 3 anti-VEGF agents, including VEGF-A blockade, MF1 and DC101, as well as one tyrosine kinase inhibitor (TKI)—sunitinib. Except for VEGFR-1 blockade, all the treatment on T241 tumor gave rise to suppression of tumor growth (sunitinib treated data not shown) and inhibition of tumor vessel angiogenesis (Figure 3 and 4). Similar to what we have seen in the JE-3 tumor model, high levels of PlGF in T241 tumors increased tumor sensitivity to VEGF-A and VEGFR-2 blockade (Figure 3).

Since PlGF is a VEGFR-1 specific ligand, we were curious about the role of VEGFR-1 in PlGF induced tumor growth inhibition and vessel normalization. Therefore, we investigated the T241 PlGF tumor vasculature remodeling in Flt1 TK^{-/-} mice in which the tyrosine kinase domain of VEGFR-1 was genetically knocked out. Compared with the wild type littermate, tumors on Flt1 TK^{-/-} mice had higher vessel density in both T241 vector and T241 PlGF group, indicating that Flt1 may transduce a negative signal of angiogenesis. In addition, in Flt1 TK^{-/-} mice, T241 PlGF tumors had relatively smoother and fewer dilated vessels than the T241 vector tumors, which demonstrate the same trend of normalization as seen in wild type mice (Figure 4E and F). This data pointed out that PlGF induced vessel normalization is dependent not only on VEGFR-1 but also on the other signaling pathways. One possible explanation may be that this phenotype is a result of the complicated modulation of VEGF-A by PlGF mentioned in paper I.

4.3 VEGF-DEPENDENT PLASTICITY OF VASCULATURE IN HEALTHY TISSUE (PAPER III)

Based on the hypothesis proposed by Dr. Judah Folkman in 1971, several approaches have been developed to block or modulate tumor angiogenesis. Tumor angiogenesis is a sophisticated procedure involving great number of gene products and different cell types. However, VEGF and its signaling pathway is the most important angiogenic factors, thus blockades of VEGF signaling are perhaps the best validated anti-angiogenic approaches. It has been 10 years since the first specific VEGF-A monoclonal antibody—bevacizumab was approved by FDA in the USA to treat certain cancers^{192, 193}. In clinical practice, the side effects caused by anti-VEGF agents attract more and more attention nowadays. In order to explore the mechanism behind of anti-VEGF agents related side effects, we performed a series of preclinical experiments on healthy mice using systemic drug administration.

The mice were randomly divided into two groups and treated with a control IgG, or a specific anti-VEGF-A IgG. In order to know which receptor was the major receptor responsible for vessel alteration from VEGF-A blockade, two more groups of mice were given MF1 or DC101. The dosages we applied were previously seen to be able to modify tumor angiogenesis. The vessels in all organs were checked under the confocal microscope after being marked with an anti-CD31 antibody. Notably, even though the drugs were delivered systemically, different tissues reacted to different extents, suggesting vessels in various tissues had a distinctive sensitivity to agents blocking the VEGF pathway. (See the table below, comparison of vessel density of anti-VEGF drugs treated tissue with that of vehicle treated tissue.)

Impact of Anti-VEGF Blockades on Vasculature of healthy mice

	Endocrine organs			Gastrointestinal tracts							Brain							Muscle								
	Thyroid	Adrenal cortex	Pancreatic islet	Gastric wall	Small intestine wall	Small intestine villi	Colon wall	Ovary	Uterus	Liver	Pancreatic acini	Thymus	Renal cortex	Glomerulus	Olfactory bulb	Cerebral cortex	Hypothalamus	Cerebellum	Medulla oblongata	Myocardium	Intrinsic lingual	Skeletal muscle	Bone marrow	Retina	Adrenal medulla	
Anti-VEGF-A	***	***	***	**	**	**	*	*	***	*	***	**	***	*	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Anti-VEGFR2	***	***	**	*	**	*	*	*	**	*	*	**	***	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns
Anti-VEGFR1	ns	ns	ns	ns	ns	ns	ns	*	*	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns

*: P<0.05; **: P<0.01; ***: P<0.001; ns: no significant difference

In most tissues, the vasculatures regressed in response to VEGF-A and VEGFR-2 blockades. In the endocrine organs that are physiologically more active, the vessels were inhibited the most. An example of this would be in the thyroid, nearly 60% reduction of vascular density was observed (Figure 1).

Generally, VEGFR-1 blockade slightly increased the vessel area but did not change the vessel density significantly except in the ovaries and uterus. Certainly, as shown by hematoxylin and eosin (H&E) staining, there were no detectable structural changes in any tissue. (Figure 1-4)

Interestingly, tissues in five body compartments, including brain, muscle, bone marrow, retina and adrenal medulla did not respond to any of these three anti-VEGF drugs, at least when the mice were treated with the doses that we gave. (Shown in the supplementary data)

In order to further understand the effect of anti-VEGF-A therapy on healthy tissues, we focused on the most sensitive organ—thyroid, and investigated further. By using the hypoxia probe pimonidazole and examining levels of hypoxia in thyroid tissue, we saw the treated thyroid tissue were more hypoxic (Figure 5G). In addition, the immunohistochemical staining of cleaved caspase-3 illustrated that a higher percentage of vessel ECs underwent apoptosis in the treated thyroid (Figure 5A). We also performed a drug withdrawal experiment to see how stable the anti-VEGF-A induced vessel regression was. The vessel density returned to untreated level approximately 14 days after drug cessation (Figure 5B and C).

As mentioned above, the thyroid vessels numbers were dramatically reduced by anti-VEGF-A treatment, so we also determined the extent by which the function of thyroid could be affected. We checked the thyroid hormone level in mouse serum and saw that the free thyroxine (T4) level was significantly impaired after only two weeks of treatment (Figure 5F). Based on this, we wondered whether the change in thyroid function was due to the dysfunctional thyroid vessels. We used dextran perfusion assay described above, to determine the health of treated thyroid vessels. The perfusion assay showed less general perfusion due to fewer vessels in the treated thyroid, even through the average perfusion of each vessel was not altered in response to VEGF-A blockade, the treated thyroid showed less blood perfusion because of the lower density of vessels (Figure 5E). Additionally, according to TEM imaging, the endothelial fenestration of blood ECs were completely suppressed by anti-VEGF-A, leading to an increased number of endothelial caveoli (Figure 5H).

4.4 FGF-2 PROMOTES LYMPHANGIOGENESIS AND TUMOR METASTASIS VIA VEGFR-3 INDUCED LEC SPROUTING (PAPER IV)

It is well known that VEGF-C is one of the most important growth factors that controls lymphangiogenesis and promotes lymphatic metastasis^{130, 133, 152}, and in LECs, VEGFR-3 is the major receptor of VEGF-C. FGF-2 was also identified as a pro-lymphangiogenesis factor in previous published papers^{65, 194}. One study has shown that the VEGFR-3 blockade inhibited FGF-2-induced lymphangiogenesis in a mouse cornea model, but the mechanism underlying this result were not investigated⁶⁵. In this paper, our data revealed the mechanism behind the collaborative interplay between FGF-2 and VEGF-C in promoting angiogenesis, lymphangiogenesis and tumor metastasis.

In order to understand the cellular and molecular effects of VEGF-C or FGF-2 on LECs, we treated LECs with VEGF-C, FGF-2, or VEGF-C plus FGF-2. Both VEGF-C and FGF-2 could independently stimulate proliferation and migration of LECs (Figure 2A, H and I). Furthermore, the mRNA levels of FGFR-1 and VEGFR-3 in LECs were increased by both VEGF-C and FGF-2 separately (Figure 2E and F). The protein level of phosphorylated intracellular signaling molecules, including p-Akt, p-ERK1/2 and p-rpS6, were also increased by both VEGF-C and FGF-2 stimulation (Figure 2B and C). In addition, in order to validate that FGFR-1 was responsible for FGF-2 stimulated LECs activation, DNA of all FGFRs were detected by PCR, the data showed that *Fgfr1* was expressed in LEC (Figure 2D) but *Fgfr2*, *Fgfr3*, and *Fgfr4* reminded very weak or undetectable. To confirm this data, we performed siRNA knockdown of *Fgfr1*. knockdown of *Fgfr1* abolished FGF-2 stimulated LEC proliferation (Figure 2G).

Using a mouse cornea model, we put a tiny piece of polymer pellet containing VEGF-C or FGF-2, VEGF-C plus FGF-2, into the artificial micropocket on the avascular cornea. Six days later, the corneas were collected to check for neovascularization. Visual inspection of the corneas showed remarkable new blood vessel formation in all treated groups (Figure 1A). The analysis of LYVE-1⁺ lymphatic vessels and CD31⁺ blood vessels showed that either VEGF-C or FGF-2 strikingly promoted angiogenesis and lymphangiogenesis, especially the

FGF-2 seemed to have stronger angiogenic effect than VEGF-C. Additionally, implantation of micropellets containing both FGF-2 and VEGF-C led to synergistic hematoangiogenesis and lymphangiogenesis (Figure 1C, G and H). If one looked closely at the LECs, dramatic tip formations were triggered by both FGF-2 and VEGF-C (Figure 3A).

From all the experiments above, we saw very similar effects of FGF-2 and VEGF-C. This fact gave rise to the hypothesis that FGF-2 and VEGF-C may share the same signaling pathway to initiate the similar outcomes.

To further discern the major role of FGFR-1 or VEGFR-3 on hematoangiogenesis and lymphangiogenesis, we tried to block these two signaling pathways with neutralizing antibodies—anti-FGFR-1 and anti-VEGFR-3. The data from *in vitro* experiments exhibited that on one hand, anti-FGFR-1 treatment inhibited the proliferation and migration of LEC induced by FGF-2 but not VEGF-C. On another hand, anti-VEGFR-3 treatment could only inhibit LEC proliferation and migration promoted by VEGF-C but not FGF-2. This result demonstrated that FGF-2 and VEGF-C could independently stimulate LEC via their own receptors. We then performed an antibody blockade experiment *in vivo*. Consistent with the *in vitro* assay, anti-FGFR-1 inhibited FGF-2 induced lymphangiogenesis as well as hematoangiogenesis in mouse cornea (Figure 2K). Meanwhile, anti-VEGFR-3 treatment reduced cornea lymphangiogenesis and the number of LEC filopodia promoted by both FGF-2 and VEGF-C, indicating that VEGFR-3-mediated LEC tip formation was required for both FGF-2 and VEGF-C induced lymphangiogenesis (Figure 3B). Notably, anti-VEGFR-3 did not affect hematoangiogenic activity of either FGF-2 or VEGF-C (Figure 3C).

In order to explore whether collaboration of FGF-2 and VEGF-C synergistically promote tumor hematoangiogenesis and lymphangiogenesis, we established T241 fibrosarcoma cell lines which stably overexpress FGF-2 or VEGF-C by gene transfection. T241 FGF-2 or VEGF-C cells were separately injected into mice or mixed together at ratio of 1:1 prior inoculation.

As expected from our previous finding, both FGF-2 and VEGF-C overexpression significantly accelerated tumor growth. Co-existence of these two factors led to the fastest growth rate (Figure 4A). Consistent with the mouse cornea assay, FGF-2 and VEGF-C dramatically stimulated tumor angiogenesis as well as intratumoral lymphatic vessel formation (Figure 4B and 5A). We then wanted to know how much the high level of vascularization contributed to tumor metastasis. We removed the primary tumors when they reached to 1.5cm³, and kept the mice for extra 2 weeks. At the endpoint, all mice were sacrificed and examined for subaxillary lymph nodes and lung metastases. We checked under the microscope and found there were no metastatic nodules found in the lungs of T241 FGF-2 tumor bearing mice. Around 40% of VEGF-C tumor-bearing mice got lung metastases. And up to 70% of T241 FGF-2 plus T241 VEGF-C tumor-bearing mice development pulmonary metastases (Figure 4D and E). Examination of sentinel lymph nodes revealed that less than 40% of T241 FGF-2 tumor-bearing mice had enlarged lymph nodes, while all the mice in the other two groups developed subaxillary lymph nodes metastasis (Figure 5D). Compared with

the VEGF-C group, metastatic lymph nodes in FGF-2 plus VEGF-C tumor bearing mice were larger and had a greater mass (Figure 5C, E and F). Analysis of green fluorescent protein(GFP) signal in tumor cells and H&E staining validated the lung and lymph node metastases (Figure 4F and 5G). Taken together, these data demonstrate that FGF-2 and VEGF-C collaboratively accelerate pulmonary and lymph node metastases by stimulating hemato- and lymph-angiogenesis.

As shown in figure 5H, VEGF-C bind to VEGFR-3 on LECs and stimulate LEC proliferation, migration and tip formation, while FGF-2 independently triggers LEC proliferation and migration by activating FGFR-1. However, VEGF-C-VEGFR-3 initiated LEC tip formation is the necessity for FGF-2-induced lymphangiogenesis. Simultaneously, both VEGF-C and FGF-2 promote hematoangiogenesis via signal transduction by VEGFR-2 or FGFRs on blood vessel ECs. Therefore, VEGF-C and FGF-2 collaboratively facilitate tumor metastasis through both blood vessels and lymphatic vessels.

5 CONCLUSION AND PROSPECTIVE

5.1 DUAL ROLES OF PLGF ON TUMOR ANGIOGENESIS

In VEGF-A positive tumor and VEGF-A-null tumor, overexpression of PlGF resulted in different alteration on tumor growth and vessel remodeling. Both sets of results can be found from previous studies in different research groups. To uncover the underlying mechanisms of these conflicting phenomena will answer many questions existing in the field.

In order to explain the dual roles of PlGF, we should exam the existing research that has been conducted in the field. Firstly, it is known that the VEGF-A-VEGFR-2 signaling pathway is the major trigger of new vessel formation, This is despite VEGF-A having a higher binding affinity to VEGFR-1, which can only be activated very weakly. Activation of VEGFR-1 has an uncertain effect on angiogenesis. Secondly, it has been reported that VEGF-A and PlGF heterodimerize with each other intracellularly and bind preferentially to VEGFR-1 instead of VEGFR-2. Due to the formation of heterodimers, the level of tumor cell secreted VEGF-A homodimers are decreased, thus reducing activation of VEGFR-2, and resulting in reduced angiogenesis and tumor growth rates. Conversely, when overexpressing PlGF in VEGF-A negative tumors, all the excess PlGF molecules are secreted as homodimers and have no chance to alter the number of host derived VEGF-A homodimers. Furthermore, numerous PlGF homodimers occupy more binding sites on VEGFR-1, thus saturating this receptor and pushing VEGF-A homodimers to bind to VEGFR-2, leading to enhanced angiogenesis, vascular permeability, and tumor growth signals (Paper I, Figure 4).

5.2 SIGNALING MODULATION BY CROSS COMMUNICATION BETWEEN PROTEINS

Data from paper I and paper II showed that PlGF-VEGFR-1 negatively modulated tumor angiogenesis when coexpressed with VEGF-A in the same cell. Based on previous research, PlGF may suppress tumor angiogenesis through the following mechanisms. The first mechanism may be due to activation of VEGFR-1 by PlGF. Knockout of *Vegfr1* in mice causes excessive proliferation of embryonic ECs and vessel formation¹⁴². This hints that VEGFR-1 activation may be responsible for PlGF induced angiogenic inhibition. In paper II, we have further evidence of VEGFR-1 transduced negative signaling—if we block VEGFR-1 downstream signal by genetic deletion of the tyrosine kinase domain, the inhibition of angiogenesis by PlGF overexpression became slightly weaker. The second mechanism may involve trapping VEGF-A on VEGFR-1. Knockout of Tyrosine kinase domain on *Vegfr1* or *Plgf* did not result in hyper-vascularization shown in *Vegfr1*^{-/-} mice^{143,138}, suggesting that the binding sites of VEGFR-1 are sufficient for suppressing excessive angiogenesis without VEGFR-1 signaling capability. Meanwhile, it has been shown that the signal transduced by VEGF-A-VEGFR-1 binding is very weak even though the binding affinity of VEGF-A to VEGFR-1 is about 10 times of that of VEGF-A binding to VEGFR-2¹⁹⁵. These data suggest the VEGFR-1 may serve as a decoy receptor for VEGF-A to reduce the promotion of angiogenesis. The final possible mechanism may be due to reduction of VEGF-A

homodimers. Dr. Eriksson reported that PlGF antagonized VEGF-induced angiogenesis and tumor growth by formation of PlGF-1/VEGF heterodimers¹⁹⁶. Later, another publication verified this initial finding by Dr. Eriksson that overexpression of PlGF in tumor cells reduced secretion of VEGF-A homodimers. In addition to this confirmation, it was also seen that even if all PlGF was trapped in the cells by endoplasmic reticulum retention signal peptide preventing its secretion from cells, overexpression of PlGF still can inhibit tumor angiogenesis¹³⁹. Taken together, this evidence shows that PlGF and VEGFR-1 can interact with VEGF-A and interfere with VEGF-A-VEGFR-2 induced angiogenesis at different levels, including affecting VEGF-A production, VEGF-A-VEGFR-2 binding and by negative angiogenic signaling from activation of VEGFR-1 upon ligand binding.

Actually, there are other elegant signaling control systems capable of regulating angiogenesis. One such example is Angs and TIE receptors system(see 1.1.4.4).

5.3 TARGETING TREATMENT

In Paper III, VEGF neutralizing antibodies resulted in systemic vessel reduction in most of normal tissue and caused abnormal organ functions. To avoid such a wide range of side effects, a novel anti-angiogenic drug specially targeting the tumor vessels would be the best solution. To develop this kind of anti-angiogenic agent with strong specificity to the tumor, specific molecular signatures of the tumor vasculature need to be identified. These specific cell signatures have to be expressed on cell surface in order to guide the targeted anti-tumor agent to the tumor.

To date, several cell surface molecules that are specifically overexpressed on tumor vessels have been found, such as, tumor endothelial marker 1 (TEM1), TEM5, TEM7 and TEM8^{197, 198, 199}. Notably, these cell markers highly or specially expressed in the tumor also participate actively in physiological process²⁰⁰, therefore, more details on the differences between physiological angiogenesis and pathological angiogenesis are still required.

5.4 COMBINED TREATMENT OF MALIGNANT CANCER

The side effects of anti-VEGF drugs are still challenging, however, the therapeutic outcomes obtained from anti-VEGF treatment have been validated in different models. We have seen the following benefits: (1) The immature vessels could not survive, leading to vessel regression²⁰¹. (2) The tumor IFP was reduced and the delivery of other anti-tumor drug, macromolecules and oxygen was increased, therefore the efficiency of chemotherapy and radiotherapy was improved^{202, 203, 204}. (3) The permeability of tumor vessels was reduced as well as the risk of tumor cell intravasation and distal metastasis^{49, 205, 206}.

Another way to enhance anti-tumor efficacy and reduce drug toxicity is to combine different therapies and minimize the dose of each drug. As mentioned above, the vessel modification by anti-VEGF treatment may increase the curative effect of conventional chemotherapeutics or radiotherapy. Our recent study has demonstrated that anti-angiogenic TKIs—such as

sunitinib (commercially named as Sutent, Pfizer) significantly improved tumor bearing mice survival by reducing chemotoxicity of cyclophosphamide (CTX) and carboplatin²⁰⁷.

In another study, Dr. Bruns²⁰⁸ et al. combined DC101 with gemcitabine to treat pancreatic tumors and found increased cell death and decreased cell proliferation. One research added VEGF-TRAP to paclitaxel treatment and reduced ovarian tumor burden²⁰⁹. Zips and colleagues delayed the squamous carcinoma growth by combination of vatalanib (PTK787, Bayer Schering and Novartis) and radiotherapy²¹⁰. Moreover, combination of anti-hematoangiogenesis and anti-lymphangiogenesis agents showed better therapeutic outcomes in controlling tumor development and metastasis than a single anti-angiogenic approach^{211, 212}.

5.5 BIOMARKERS FOR TREATMENT OUTCOMES AND PROGNOSIS

In clinical practice, we not only choose the better therapeutic regimen for the patients according to indications and contraindications, but also select treatment of patients by certain biomarkers that can did prediction of the therapeutic efficacy and prognosis. With some level of prediction, the treatment may result in very modest benefits and cause harmful side effects. A perfect biomarker should have the following features: (1) Sensitivity: its levels should change consistently together with the particular phenotype. (2) Feasibility: it should be easy to be detected the samples and the samples should be easy to obtain. The detection method should be quick, accurate and economical. (3) Specificity: it should be specific for a particular phenotype.

It has been reported that the use of anti-PIGF on anti-VEGF drug resistant tumors led to inhibition of tumor growth²¹³. This is in contrast to another study that did not show inhibition of angiogenesis and tumor growth in various tumors treated by PIGF blockade, except on a VEGFR-1 overexpression tumor²¹⁴. Under these conditions, the expression level of VEGFR-1 in a tumor may be a potential biomarker for anti-PIGF treatment.

In paper II, mouse and human tumors with high PIGF expression were more sensitive to anti-VEGF drug than the low PIGF expressing tumors. In this case, the expression level of PIGF in a tumor may serve as a potential biomarker for anti-VEGF treatment.

Increasing evidences including our unpublished data, show that VEGF-B level in tumor is correlated with cancer metastasis and survival^{121, 215}, thus VEGF-B can be a potent predictor for prognosis.

Another candidate is FGF-2. Many researchers put efforts on validating the prognostic ability of FGF2 levels in urine or serum of cancer patients, however, the results are still ambiguous^{59, 216, 217}. Notably, FGF-2 has no signal peptide for secretion, subsequently, expression level of FGF-2 in cells does not necessarily correlate with the amount of FGF-2 outside the cells. Yet, cell damage and exocytosis has been confirmed as the potent alternative ways of releasing the growth factor to the ECM²¹⁸.

Plenty of well-designed clinical studies are required to validate the potential of a new biomarker. Before that, we can do a preliminary assessment by checking and analyzing data from the clinical databases.

5.6 VEGFR-3 PLAYS THE CRUCIAL ROLE IN LYMPHANGIOGENESIS

In paper IV, anti-VEGFR-3 treatment blocked FGF-2 stimulated lymphangiogenesis in mouse corneas by preventing LEC tip formation. This means that VEGFR-3 activation is indispensable in lymphangiogenesis even though FGF-2 can independently induce LEC proliferation and migration *in vitro*. Upon reviewing the literature, more similar cases can be found. One of our recent paper uncovered that Tumor necrosis factor alpha (TNF- α) promoted lymphangiogenesis was blocked by VEGFR-3 neutralizing antibody which led to reduction in the number of the LEC tips²¹⁹. Another study reported that hepatocyte growth factor (HGF) induced lymphangiogenesis was partly blocked by a soluble VEGFR-3²²⁰. All these results suggest that VEGFR-3 may play a crucial and irreplaceable role in inhibition of LEC tip formation during lymphangiogenesis under the control of many different factors. Certainly, there are still some questions that need to be answered. What is the active ligand for VEGFR-3 in FGF-2 induced angiogenesis? Is it possible that FGF-2 can directly activate VEGFR-3? Did FGF-2 lead to an increased expression of VEGFR-3 and VEGF-C or VEGF-D? In future, we first can measure the expression level of VEGFR-3, VEGF-C and VEGF-D upon FGF-2 stimulation. Furthermore, we need to check which cell type is responsible for the production of VEGFR-3, VEGF-C and VEGF-D. The VEGF-C and VEGF-D blockade treatment can provide the information whether VEGF-C and VEGF-D are the only activator of VEGFR-3.

5.7 ANIMAL MODELS IN PRECLINICAL STUDIES

Because there are a few similarities in physiological and pathological states between humans and the other species, various types of animal models have been built up with the purpose of understanding the progression of human diseases. However, more and more translational studies revealed that the therapeutic effects seen from animal models could not be reproduced in clinical practice. We shall be careful when translating laboratory experimental data to clinical situations. Considering the differences between a group of experimental animals and a group of clinical patients, we can see why the difficulties exist. Firstly, genetic divergence of evolutionarily between creatures means that different species certainly do not react exactly the same way to different pathogenic situations or treatments. Secondly, there are many more individual variations among the humans than experimental animals, that are genetically identical and live under controlled environments. Nevertheless, animal models are still required for preclinical studies. Importantly, we should always set the appropriate control groups to minimize the interference and error. In addition, extra attentions should be paid to the “three R” principle when performing the animal experiment, reduce, refine and replace.

6 ACKNOWLEDGEMENTS

At the completion of my thesis, I would like to express my great gratitude to all who have helped and supported me during my postgraduate study in the past 5 years:

Firstly, to Karolinska Institute, thank you for providing me a resourceful, encouraging and peaceful environment in which I could enrich my knowledge and share my ideas freely and efficiently. Thanks to the China Scholarship Council which supported me with 4 years' stipend.

I would like to give my utmost sincere thanks to my supervisor, **Professor Yihai Cao**, for offering me a chance to work in your laboratory under your supervision, for your wonderful scientific ideas and instructive advices on my project. In the past few years, you encouraged me with your fortitude character, impressed me with your agile mind and very high degree of knowledge. From you, I realized how hard yet how exciting the research work can be, I also got to know how much efforts an excellent scientist has to invest in his work. Without you, I could not grow stronger and tougher. Thank you for making me understand more about what to do and how to do in future.

My heartfelt gratitude should be sent to my co-supervisor and confidant-**Dr. Kayoko Hosaka**, for your constant encouragement and patient guidance. We shared most of the fun and happiness in our life, even more preciously, we went through all the failures and disappointments together. Thank you for taking care of me like my beloved elder sister.

I can complete my projects and reach to the end point of my PhD program not only based on the help from my supervisors but also owing to support and assistance from my friends, colleagues, collaborators and many other people.

First, I would bring my great appreciation to the group members:

Dear lovely **Sharon Lim**, my kind-hearted and frank sister, thank you so much for sharing our happy meals, our funny stories, our critical comments on those guys and our little secrets. You are an earnest girl both at work and in life, I believe that your passion to the world must bring you a very bright future.

Dr. Hong Ji, thank you for being my close friend. I have learned quite a lot of truth from you about how to behave like a real charming lady.

Dr. Junwei Zhang, I have to tell you that you are a perfect ShiXiong, whatever help I need, you have always be supportive. Thank you for collaborating with me on almost all my projects, I hope I will have more chances to ask and enjoy your help. I will never forget your extremely delicious food.

Dr. Yunlong Yang, the smart one, thank you for always providing me a different thinking of the research work as well as the other aspects of the world. I like the debate competition between us.

Dear small P, **Patrik Andersson**, thank you for your work on my PCR experiments, your brilliant jokes brought me a lot of fun. You are the youngest in the lab forever in my mind, I promise.

The cute girl—**Jennifer Honek**, we joined Professor Cao's group during the same period and almost went through all the important steps of our PhD education together. Thank you for being a good company in various ways. Wish you a happy and sunny future!

Dr. Lasse Janssen, you have been the idol for us since I met you, thank you for demonstrating your wonderful and colorful life to me—you are an outstanding young researcher, a passionate singer, a sincere friend and I believe you are an excellent husband for your wife because of your flawless character.

PhD student **Ziquan Cao**, thank you for your friendship, you are the first friend I made in the lab, those nice pictures you took captured all the very good moments and my happiness in Sweden.

Dr. **Renhai Cao** and **Li Chen**, thank you for sharing your experience on staining and confocal techniques. Especially, it is very helpful that both of you told me a lot about the daily life in Sweden.

I also owe my sincere gratitude to The Three Musketeers from Japan—**Takahiro Seki**, **Masaki Nakamura**, **Hideki Iwamoto**, you are all real men with immense sense of responsibility to your work and your families. Thank you for your wise suggestions to my work, and it is grateful to learn accuracy and rigorous attitude to work from you.

To the younger group members, **Carina Fischer**, **Jian Wang**, **Mamiko Kiyohara** and **Wenyi Zheng**, thank you all for bringing me fresh vitality and hope.

To the former friends and colleagues who have left the lab, Ying Zhao, Jeannette Söderberg, Ceylan Sönmez, Olivier Dubey, Pegah Rouhi, Eva-Maria Hedlund, Danfang Zhang, Yuan Xue, Xiaoyun Chen, Meili Sun, thank you all for your kindness and grateful suggestions to me during the past few years.

I would give my acknowledgement to **Marcus Ladds** who carefully checked the thesis.

Thanks to the other MTCers: Technicians-Magnus Bjurström and Torbjörn Laggar, Educational administrator-Anita Wallentin, Director of third level studies-Dr. Velmurugesan Arulampalam, Katrin Pütsep, HR administrator-Lina Rejnö, Personnel supervisor-Helene Stambeck, and Professor Ingemar Ernberg. Thank you all for always offering me your help in time whenever I approached to you.

My sincere thanks should also go to the staffs working in MTC animal facility: Torunn Söderberg, Kenth Andersson, Elin Hildekrans, Helen Braxenholm and the KI veterinary - Anna Granlund. Thank you for taking care of my animals and making the animal house to a comfortable working place.

Thanks to Birgitta Wester for running tremendous amount of FACS samples for me, without your help, it is impossible to complete my project now.

Dr. Fredrik Tholander at MBB, one of my best collaborators, thank you for providing me your super professional assistance in HPLC and making great progress for our projects. **Dr. Kjell Hultenby** in LABMED, thank you for teaching me how to analysis my images and moreover, you have tried your best to collect electronic microscope data for me.

I would like to take the opportunity to thank all my friends at MTC: Qinzi Yan, Hai Li, Xiaogang Feng, Yu Gao, Honglei Zhao, Sadia Salam, Xingqi Chen, Yao Shi, Soazig Le Guyon, we had interesting talks on various topics and enjoyed happy lunch time together.

I feel grateful to all the excellent stomatologists who have helped me: Professor Weidong Tian, Professor Wei Tang, Professor Hang Wang, Professor Lei Liu, Professor Yunfeng Lin, Professor Shengwei Li, Jingang Xiao, Yongdai Shen, Wei Jing, Weihau Guo, Xiaoyu Li, Ling Wu, Thank you for keeping close touch with me even though I am far away from you. It is you who keep my knowledge of stomatology updated.

To my dear friends in China: Fan Feng, Renke Wang, Shujuan Guo, Fenchen Chen, Jing Guo, Hongxia Dan, Jiazeng Dong, Yan He, Yao Shu, Jingyi Zheng, Ya Wang, Jian Yang and Meng You. Thank you for encouraging me with your positive heart and mind, as well as sharing your stories and reflection on life with me.

My sincere thanks are also given to my mentor Dr. Sonia Lain, my public defense opponent Dr. Jenny L Persson, members of the examination board: Dr. Charlotte Rolny, Professor Laszlo Szekely, Professor Keiko Funa, thank you for offering me valuable suggestions on my thesis.

Last but not least, I would like to express my gratitude to my beloved family: My mother Lan and my father Min, I am greatly indebted to you and your love since my childhood. No matter where I am, my heart is always beside you, I have grown up and will not be scared any more. To my husband wawa, thank you for your loving considerations and all you have done for me. I can never say enough words to show my appreciation to you.

7 REFERENCES

1. Risau W, Flamme I. Vasculogenesis. *Annu Rev Cell Dev Biol* **11**, 73-91 (1995).
2. Alitalo K. The lymphatic vasculature in disease. *Nat Med* **17**, 1371-1380 (2011).
3. Thiriet M. Anatomy and Physiology of the Circulatory and Ventilatory Systems. *Anatomy and Physiology of the Circulatory and Ventilatory Systems* **6**, 1-585 (2014).
4. Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG. Lymphangiogenesis and lymphatic vessel remodelling in cancer. *Nature Reviews Cancer* **14**, 159-172 (2014).
5. Baluk P, *et al.* Functionally specialized junctions between endothelial cells of lymphatic vessels. *Journal of Experimental Medicine* **204**, 2349-2362 (2007).
6. Cardiovascular Mathematics: Modeling and Simulation of the Circulatory System. *Cardiovascular Mathematics: Modeling and Simulation of the Circulatory System* **1**, 1-522 (2009).
7. Bikfalvi A. Angiogenesis: health and disease. *Ann Oncol* **17 Suppl 10**, x65-70 (2006).
8. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. *Nat Med* **6**, 389-395 (2000).
9. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. *Am J Physiol Cell Physiol* **282**, C947-970 (2002).
10. Polverini PJ. Angiogenesis in health and disease: insights into basic mechanisms and therapeutic opportunities. *J Dent Educ* **66**, 962-975 (2002).
11. Rosenkilde MM, Schwartz TW. The chemokine system -- a major regulator of angiogenesis in health and disease. *APMIS* **112**, 481-495 (2004).
12. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. *Circ Res* **97**, 512-523 (2005).
13. Gerhardt H, Betsholtz C. Endothelial-pericyte interactions in angiogenesis. *Cell Tissue Res* **314**, 15-23 (2003).
14. Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. *Journal of Biochemistry* **153**, 13-19 (2013).
15. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. *Nature Reviews Cancer* **10**, 505-514 (2010).
16. Hunter J. A treatise on the blood, inflammation, and gun-shot wounds. 1794. *Clin Orthop Relat Res* **458**, 27-34 (2007).
17. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* **285**, 1182-1186 (1971).
18. Risau W, *et al.* Vasculogenesis and angiogenesis in embryonic-stem-cell-derived embryoid bodies. *Development* **102**, 471-478 (1988).
19. Poole TJ, Coffin JD. Vasculogenesis and angiogenesis: two distinct morphogenetic mechanisms establish embryonic vascular pattern. *J Exp Zool* **251**, 224-231 (1989).
20. Pardanaud L, Yassine F, Dieterlenlievre F. Relationship between Vasculogenesis, Angiogenesis and Hematopoiesis during Avian Ontogeny. *Development* **105**, 473-485 (1989).
21. Carmeliet P. Angiogenesis in health and disease. *Nat Med* **9**, 653-660 (2003).
22. Carmeliet P. Angiogenesis in life, disease and medicine. *Nature* **438**, 932-936 (2005).
23. Gerhardt H, *et al.* VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. *Journal of Cell Biology* **161**, 1163-1177 (2003).
24. Nakatsu MN, *et al.* Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. *Microvascular Research* **66**, 102-112 (2003).
25. Hellstrom M, Phng LK, Gerhardt H. VEGF and Notch Signaling The Yin and Yang of Angiogenic Sprouting. *Cell Adhesion & Migration* **1**, 133-136 (2007).

26. Hellstrom M, *et al.* Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. *Nature* **445**, 776-780 (2007).
27. Li WQ, Chen J, Deng M, Jing Q. The zebrafish Tie2 signaling controls tip cell behaviors and acts synergistically with Vegf pathway in developmental angiogenesis. *Acta Biochimica Et Biophysica Sinica* **46**, 641-646 (2014).
28. Djonov V, Schmid M, Tschanz SA, Burri PH. Intussusceptive angiogenesis - Its role in embryonic vascular network formation. *Circulation Research* **86**, 286-292 (2000).
29. Makanya AN, Hlushchuk R, Djonov VG. Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling. *Angiogenesis* **12**, 113-123 (2009).
30. Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: A novel mechanism of tumor angiogenesis. *Microvascular Research* **51**, 260-272 (1996).
31. Gianni-Barrera R, Trani M, Reginato S, Banfi A. To sprout or to split? VEGF, Notch and vascular morphogenesis. *Biochemical Society Transactions* **39**, 1644-1648 (2011).
32. Gianni-Barrera R, *et al.* VEGF over-expression in skeletal muscle induces angiogenesis by intussusception rather than sprouting. *Angiogenesis* **16**, 123-136 (2013).
33. Dimova I, *et al.* Inhibition of Notch signaling induces extensive intussusceptive neo-angiogenesis by recruitment of mononuclear cells. *Angiogenesis* **16**, 921-937 (2013).
34. Styp-Rekowska B, Hlushchuk R, Pries AR, Djonov V. Intussusceptive angiogenesis: pillars against the blood flow. *Acta Physiologica* **202**, 213-223 (2011).
35. Ricci-Vitiani L, *et al.* Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. *Nature* **468**, 824-828 (2010).
36. Maniotis AJ, *et al.* Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. *Am J Pathol* **155**, 739-752 (1999).
37. Shirakawa K, *et al.* Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. *Cancer Res* **62**, 560-566 (2002).
38. Paulis YWJ, Soetekouw PMMB, Verheul HMW, Tjan-Heijnen VCG, Griffioen AW. Signalling pathways in vasculogenic mimicry. *Biochimica Et Biophysica Acta-Reviews on Cancer* **1806**, 18-28 (2010).
39. Holash J, *et al.* Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. *Science* **284**, 1994-1998 (1999).
40. Rubenstein JL, *et al.* Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. *Neoplasia* **2**, 306-314 (2000).
41. Kienast Y, *et al.* Real-time imaging reveals the single steps of brain metastasis formation. *Nat Med* **16**, 116-122 (2010).
42. Hopfelkreiner I. Histogenesis of Hemangiomas - an Ultrastructural-Study on Capillary and Cavernous Hemangiomas of the Skin. *Pathology Research and Practice* **170**, 70-90 (1980).
43. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. *J Clin Oncol* **25**, 4298-4307 (2007).
44. Wang Y, Oliver G. Current views on the function of the lymphatic vasculature in health and disease. *Genes Dev* **24**, 2115-2126 (2010).
45. Tammela T, Alitalo K. Lymphangiogenesis: Molecular mechanisms and future promise. *Cell* **140**, 460-476 (2010).
46. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. *Nature* **438**, 946-953 (2005).
47. Platonova N, *et al.* Evidence for the interaction of fibroblast growth factor-2 with the lymphatic endothelial cell marker LYVE-1. *Blood* **121**, 1229-1237 (2013).
48. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. *Semin Oncol* **29**, 3-9 (2002).

49. Lee TH, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. *J Biol Chem* **278**, 5277-5284 (2003).
50. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. *Current Opinion in Genetics & Development* **15**, 102-111 (2005).
51. Ocak I, Baluk P, Barrett T, McDonald DM, Choyke P. The biologic basis of in vivo angiogenesis imaging. *Frontiers in Bioscience* **12**, 3601-3616 (2007).
52. Hashizume H, *et al.* Openings between defective endothelial cells explain tumor vessel leakiness. *American Journal of Pathology* **156**, 1363-1380 (2000).
53. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. *American Journal of Pathology* **160**, 985-1000 (2002).
54. Weis SM, Cheresch DA. Tumor angiogenesis: molecular pathways and therapeutic targets. *Nature Medicine* **17**, 1359-1370 (2011).
55. Cao Y. Tumor angiogenesis and molecular targets for therapy. *Front Biosci (Landmark Ed)* **14**, 3962-3973 (2009).
56. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine Growth Factor Rev* **16**, 159-178 (2005).
57. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. *Mol Cell Biol* **6**, 4060-4066 (1986).
58. Taraboletti G, D'Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. *Am J Pathol* **160**, 673-680 (2002).
59. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. *J Clin Oncol* **19**, 1207-1225 (2001).
60. Takahashi JA, *et al.* Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. *Proc Natl Acad Sci U S A* **87**, 5710-5714 (1990).
61. Vasileiou C, *et al.* Effect of ET-1, FGF-2, and HGF on intracellular steroidogenesis in prostate cancer cells. *Journal of Clinical Oncology* **31**, (2013).
62. Haley EM, Kim Y. The role of basic fibroblast growth factor in glioblastoma multiforme and glioblastoma stem cells and in their in vitro culture. *Cancer Letters* **346**, 1-5 (2014).
63. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. *Cancer Cell* **2**, 301-314 (2002).
64. Ribatti D. Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis. *Immunology Letters* **152**, 83-88 (2013).
65. Kubo H, Cao R, Brakenhielm E, Makinen T, Cao Y, Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. *Proc Natl Acad Sci U S A* **99**, 8868-8873 (2002).
66. Shin JW, *et al.* Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: A role for FGF signaling in lymphangiogenesis. *Molecular Biology of the Cell* **17**, 576-584 (2006).
67. Cao R, *et al.* Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. *Proc Natl Acad Sci U S A* **109**, 15894-15899 (2012).

68. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. *Science* **277**, 242-245 (1997).
69. Bondjers C, *et al.* Transcription profiling of platelet-derived growth factor-B-deficient mouse embryos identifies RGS5 as a novel marker for pericytes and vascular smooth muscle cells. *American Journal of Pathology* **162**, 721-729 (2003).
70. Xue Y, *et al.* PDGF-BB modulates hematopoiesis and tumor angiogenesis by inducing erythropoietin production in stromal cells. *Nat Med* **18**, 100-110 (2012).
71. Hosaka K, *et al.* Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis. *Nat Commun* **4**, 2129 (2013).
72. Matsumoto S, *et al.* Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. *Anticancer Res* **27**, 2409-2414 (2007).
73. Miyazaki H, *et al.* Expression of platelet-derived growth factor receptor beta is maintained by Prox1 in lymphatic endothelial cells and is required for tumor lymphangiogenesis. *Cancer Science* **105**, 1116-1123 (2014).
74. Takagi S, Hirata T, Agata K, Mochii M, Eguchi G, Fujisawa H. The A5-Antigen, a Candidate for the Neuronal Recognition Molecule, Has Homologies to Complement Components and Coagulation-Factors. *Neuron* **7**, 295-307 (1991).
75. Serini G, Bussolino F, Maione F, Giraudo E. Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy. *Journal of Internal Medicine* **273**, 138-155 (2013).
76. Guo HF, Li XB, Parker MW, Waltenberger J, Becker PM, Vander Kooi CW. Mechanistic Basis for the Potent Anti-Angiogenic Activity of Semaphorin 3F. *Biochemistry* **52**, 7551-7558 (2013).
77. Zachary I. Neuropilins: Role in Signalling, Angiogenesis and Disease. *Angiogenesis, Lymphangiogenesis and Clinical Implications* **99**, 37-70 (2014).
78. Kawasaki T, *et al.* A requirement for neuropilin-1 in embryonic vessel formation. *Development* **126**, 4895-4902 (1999).
79. Zachary I. Neuropilins: role in signalling, angiogenesis and disease. *Chem Immunol Allergy* **99**, 37-70 (2014).
80. Xu Y, *et al.* Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. *J Cell Biol* **188**, 115-130 (2010).
81. West DC, *et al.* Interactions of multiple heparin binding growth factors with neuropilin-1 and potentiation of the activity of fibroblast growth factor-2. *Journal of Biological Chemistry* **280**, 13457-13464 (2005).
82. Banerjee S, *et al.* Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. *Molecular Carcinogenesis* **45**, 871-880 (2006).
83. Suri C, *et al.* Requisite role of Angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. *Cell* **87**, 1171-1180 (1996).
84. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J. The Receptor Tyrosine Kinase Tie Is Required for Integrity and Survival of Vascular Endothelial-Cells. *Embo Journal* **14**, 5884-5891 (1995).
85. Gale NW, *et al.* Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. *Developmental Cell* **3**, 411-423 (2002).
86. Dumont DJ, *et al.* Dominant-Negative and Targeted Null Mutations in the Endothelial Receptor Tyrosine Kinase, Tek, Reveal a Critical Role in Vasculogenesis of the Embryo. *Genes & Development* **8**, 1897-1909 (1994).
87. Arai F, *et al.* Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. *Cell* **118**, 149-161 (2004).

88. Dumont DJ, Fong GH, Puri MC, Gradwohl G, Alitalo K, Breitman ML. Vascularization of the Mouse Embryo - a Study of Flk-1, Tek, Tie, and Vascular Endothelial Growth-Factor Expression during Development. *Developmental Dynamics* **203**, 80-92 (1995).
89. Thurston G, Daly C. The Complex Role of Angiopoietin-2 in the Angiopoietin-Tie Signaling Pathway. *Cold Spring Harbor Perspectives in Medicine* **2**, (2012).
90. Tammela T, *et al.* Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. *Blood* **105**, 4642-4648 (2005).
91. Shibuya M. Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E. *Cancer Sci* **94**, 751-756 (2003).
92. Yamazaki Y, Matsunaga Y, Tokunaga Y, Obayashi S, Saito M, Morita T. Snake Venom Vascular Endothelial Growth Factors (VEGF-Fs) Exclusively Vary Their Structures and Functions among Species. *Journal of Biological Chemistry* **284**, 9885-9891 (2009).
93. Shibuya M. Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E. *Endothelium* **13**, 63-69 (2006).
94. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. *Clinical Science* **109**, 227-241 (2005).
95. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. *Seminars in Thrombosis and Hemostasis* **26**, 561-569 (2000).
96. Cadena DL, Gill GN. Receptor tyrosine kinases. *FASEB J* **6**, 2332-2337 (1992).
97. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor-Cells Secrete a Vascular-Permeability Factor That Promotes Accumulation of Ascites-Fluid. *Science* **219**, 983-985 (1983).
98. Ferrara N, Henzel WJ. Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth-Factor Specific for Vascular Endothelial-Cells. *Biochemical and Biophysical Research Communications* **161**, 851-858 (1989).
99. Senger DR, Perruzzi CA, Feder J, Dvorak HF. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. *Cancer Res* **46**, 5629-5632 (1986).
100. Ferrara N. VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer* **2**, 795-803 (2002).
101. Maes C, *et al.* Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. *Mech Dev* **111**, 61-73 (2002).
102. Carmeliet P, *et al.* Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. *Nat Med* **5**, 495-502 (1999).
103. Soker S, Fidler IJ, Neufeld G, Klagsbrun M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF(165) via its exon 7-encoded domain. *Journal of Biological Chemistry* **271**, 5761-5767 (1996).
104. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* **92**, 735-745 (1998).
105. Carmeliet P, *et al.* Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* **380**, 435-439 (1996).
106. Ferrara N, *et al.* Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. *Nature* **380**, 439-442 (1996).

107. Minchenko A, Bauer T, Salceda S, Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. *Lab Invest* **71**, 374-379 (1994).
108. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. *Journal of Experimental Medicine* **201**, 1089-1099 (2005).
109. Shibuya M. Unique signal transduction of the VEGF family members VEGF-A and VEGF-E. *Biochem Soc Trans* **37**, 1161-1166 (2009).
110. Voron T, *et al.* Control of the immune response by pro-angiogenic factors. *Front Oncol* **4**, 70 (2014).
111. Nagai A, *et al.* Antiangiogenic-induced hypertension: the molecular basis of signaling network. *Gynecol Obstet Invest* **73**, 89-98 (2012).
112. Li M, Stenmark KR, Shandas R, Tan W. Effects of pathological flow on pulmonary artery endothelial production of vasoactive mediators and growth factors. *J Vasc Res* **46**, 561-571 (2009).
113. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. *FEBS Lett* **370**, 203-208 (1995).
114. Shima DT, *et al.* Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. *Mol Med* **1**, 182-193 (1995).
115. Paavonen K, *et al.* Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. *Circulation* **93**, 1079-1082 (1996).
116. Olofsson B, *et al.* Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America* **95**, 11709-11714 (1998).
117. Makinen T, *et al.* Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. *Journal of Biological Chemistry* **274**, 21217-21222 (1999).
118. Bellomo D, *et al.* Mice lacking the vascular endothelial growth factor-B gene (*Vegfb*) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. *Circulation Research* **86**, E29-E35 (2000).
119. Aase K, *et al.* Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. *Circulation* **104**, 358-364 (2001).
120. Li XR, Kumar A, Zhang F, Lee C, Tang ZS. Complicated life, complicated VEGF-B. *Trends in Molecular Medicine* **18**, 119-127 (2012).
121. Lautenschlaeger T, *et al.* Bladder Preservation Therapy for Muscle-Invasive Bladder Cancers on Radiation Therapy Oncology Group Trials 8802, 8903, 9506, and 9706: Vascular Endothelial Growth Factor B Overexpression Predicts for Increased Distant Metastasis and Shorter Survival. *Oncologist* **18**, 685-686 (2013).
122. Jayasinghe C, Simiantonaki N, Kirkpatrick CJ. VEGF-B expression in colorectal carcinomas and its relevance for tumor progression. *Histology and Histopathology* **28**, 647-653 (2013).
123. Linardou H, *et al.* The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. *Breast Cancer Research* **14**, (2012).
124. Angelescu C, *et al.* VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers. *Clinical & Translational Oncology* **15**, 313-320 (2013).

125. Anisimov A, *et al.* The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. *Sci Signal* **6**, ra52 (2013).
126. Olofsson B, *et al.* Vascular endothelial growth factor B, a novel growth factor for endothelial cells. *Proceedings of the National Academy of Sciences of the United States of America* **93**, 2576-2581 (1996).
127. Karkkainen MJ, *et al.* Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. *Nat Immunol* **5**, 74-80 (2004).
128. Karnezis T, *et al.* VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. *Cancer Cell* **21**, 181-195 (2012).
129. Skobe M, *et al.* Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. *Am J Pathol* **159**, 893-903 (2001).
130. Makinen T, *et al.* Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO J* **20**, 4762-4773 (2001).
131. Mandriota SJ, *et al.* Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. *EMBO J* **20**, 672-682 (2001).
132. Joukov V, *et al.* A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. *EMBO J* **15**, 1751 (1996).
133. Kukk E, *et al.* VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. *Development* **122**, 3829-3837 (1996).
134. Orlandini M, Marconcini L, Ferruzzi R, Oliviero S. Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. *Proc Natl Acad Sci U S A* **93**, 11675-11680 (1996).
135. Astin JW, *et al.* Vegfd can compensate for loss of Vegfc in zebrafish facial lymphatic sprouting. *Development* **141**, 2680-2690 (2014).
136. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). *Curr Top Microbiol Immunol* **237**, 31-40 (1999).
137. Carmeliet P, *et al.* Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. *Nat Med* **7**, 575-583 (2001).
138. Freitas-Andrade M, Carmeliet P, Charlebois C, Stanimirovic DB, Moreno MJ. PlGF knockout delays brain vessel growth and maturation upon systemic hypoxic challenge. *Journal of Cerebral Blood Flow and Metabolism* **32**, 663-675 (2012).
139. Hedlund EM, Hosaka K, Zhong ZD, Cao RH, Cao YH. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 17505-17510 (2009).
140. Marcellini M, *et al.* Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. *American Journal of Pathology* **169**, 643-654 (2006).
141. Pipp F, *et al.* VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. *Circ Res* **92**, 378-385 (2003).
142. Fong GH, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. *Nature* **376**, 66-70 (1995).
143. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. *Proc Natl Acad Sci U S A* **95**, 9349-9354 (1998).

144. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. *Blood* **87**, 3336-3343 (1996).
145. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. *Angiogenesis* **9**, 225-230; discussion 231 (2006).
146. Li X, Claesson-Welsh L, Shibuya M. VEGF receptor signal transduction. *Methods Enzymol* **443**, 261-284 (2008).
147. Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. *Biochim Biophys Acta* **1804**, 567-580 (2010).
148. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. *Cell* **98**, 769-778 (1999).
149. Kaipainen A, *et al.* Expression of the *fms*-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. *Proc Natl Acad Sci U S A* **92**, 3566-3570 (1995).
150. Hatva E, *et al.* Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. *Am J Pathol* **146**, 368-378 (1995).
151. Paavonen K, Puolakkainen P, Jussila L, Jahkola T, Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. *Am J Pathol* **156**, 1499-1504 (2000).
152. Valtola R, *et al.* VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. *American Journal of Pathology* **154**, 1381-1390 (1999).
153. Dumont DJ, *et al.* Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science* **282**, 946-949 (1998).
154. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. *Cancer Cell* **1**, 219-227 (2002).
155. Presta LG, *et al.* Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. *Cancer Res* **57**, 4593-4599 (1997).
156. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. *Growth Factors* **7**, 53-64 (1992).
157. Patel RD, Momi RS, Hariprasad SM. Review of Ranibizumab Trials for Neovascular Age-Related Macular Degeneration. *Seminars in Ophthalmology* **26**, 372-379 (2011).
158. Poole RM, Vaidya A. Ramucirumab: first global approval. *Drugs* **74**, 1047-1058 (2014).
159. Wong AK, *et al.* Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. *Proc Natl Acad Sci U S A* **98**, 7481-7486 (2001).
160. Sorbera LA. Aflibercept - Antiangiogenic agent vascular endothelial growth factor inhibitor. *Drugs of the Future* **32**, 109-117 (2007).
161. Karpanen T, *et al.* Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. *Cancer Research* **61**, 1786-1790 (2001).
162. Makinen T, *et al.* Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. *Nature Medicine* **7**, 199-205 (2001).
163. Netland PA, Zetter BR. Metastatic potential of B16 melanoma cells after in vitro selection for organ-specific adherence. *J Cell Biol* **101**, 720-724 (1985).
164. Lee SL, *et al.* Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. *Proc Natl Acad Sci U S A* **106**, 19485-19490 (2009).

165. Auerbach R, Auerbach W, Polakowski I. Assays for Angiogenesis - a Review. *Pharmacology & Therapeutics* **51**, 1-11 (1991).
166. Cimpean AM, Ribatti D, Raica M. A brief history of angiogenesis assays. *International Journal of Developmental Biology* **55**, 377-382 (2011).
167. Cao R, *et al.* Mouse corneal lymphangiogenesis model. *Nat Protoc* **6**, 817-826 (2011).
168. Naoi T, *et al.* The Effect of tert-Butylhydroquinone-Induced Oxidative Stress in MDBK Cells using XTT Assay: Implication of tert-Butylhydroquinone-Induced NADPH Generating Enzymes. *Journal of Veterinary Medical Science* **72**, 321-326 (2010).
169. Maghni K, Nicolescu OM, Martin JG. Suitability of cell metabolic colorimetric assays for assessment of CD4+T cell proliferation: comparison to 5-bromo-2-deoxyuridine (BrdU) ELISA. *Journal of Immunological Methods* **223**, 185-194 (1999).
170. Benton G, Arnaoutova I, George J, Kleinman HK, Koblinski J. Matrigel: From discovery and ECM mimicry to assays and models for cancer research. *Adv Drug Deliv Rev*, (2014).
171. Ehsan SM, Welch-Reardon KM, Waterman ML, Hughes CC, George SC. A three-dimensional in vitro model of tumor cell intravasation. *Integr Biol (Camb)* **6**, 603-610 (2014).
172. Coukos G, Makrigiannakis A, Amin K, Albelda SM, Coutifaris C. Platelet-endothelial cell adhesion molecule-1 is expressed by a subpopulation of human trophoblasts: a possible mechanism for trophoblast-endothelial interaction during haemochorial placentation. *Molecular Human Reproduction* **4**, 357-367 (1998).
173. Rosso R, Lucioni M. Normal and neoplastic cells of brown adipose tissue express the adhesion molecule CD31. *Archives of Pathology & Laboratory Medicine* **130**, 480-482 (2006).
174. Ordonez NG. Immunohistochemical Endothelial Markers: A Review. *Advances in Anatomic Pathology* **19**, 281-295 (2012).
175. Banerji S, *et al.* LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. *Journal of Cell Biology* **144**, 789-801 (1999).
176. Schacht V, *et al.* T1 alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. *Embo Journal* **22**, 3546-3556 (2003).
177. BreitenederGeleff S, *et al.* Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. *American Journal of Pathology* **151**, 1141-1152 (1997).
178. Ozerdem U, Stallcup WB. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. *Angiogenesis* **7**, 269-276 (2004).
179. Karram K, Chatterjee N, Trotter J. NG2-expressing cells in the nervous system: role of the proteoglycan in migration and glial-neuron interaction. *J Anat* **207**, 735-744 (2005).
180. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. *Nat Cell Biol* **7**, 870-879 (2005).
181. Ronnov-Jessen L, Petersen OW. A function for filamentous alpha-smooth muscle actin: retardation of motility in fibroblasts. *J Cell Biol* **134**, 67-80 (1996).
182. Li Z, *et al.* Cardiovascular lesions and skeletal myopathy in mice lacking desmin. *Dev Biol* **175**, 362-366 (1996).
183. Berger M, Bergers G, Arnold B, Hammerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. *Blood* **105**, 1094-1101 (2005).

184. Brown EB, *et al.* In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. *Nat Med* **7**, 864-868 (2001).
185. de Oliveira LBO, Bampi VF, Gomes CF, da Silva JLB, Rechsteiner SMEF. Morphological Characterization of Sprouting and Intussusceptive Angiogenesis by SEM in Oral Squamous Cell Carcinoma. *Scanning* **36**, 293-300 (2014).
186. Ribatti D. The controversial role of placental growth factor in tumor growth. *Cancer Lett* **307**, 1-5 (2011).
187. Marcellini M, *et al.* Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. *Am J Pathol* **169**, 643-654 (2006).
188. Schomber T, *et al.* Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. *Cancer Res* **67**, 10840-10848 (2007).
189. Bjorndahl M, Cao R, Eriksson A, Cao Y. Blockage of VEGF-induced angiogenesis by preventing VEGF secretion. *Circ Res* **94**, 1443-1450 (2004).
190. Vilorio-Petit A, *et al.* Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. *EMBO J* **22**, 4091-4102 (2003).
191. Rolny C, *et al.* HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. *Cancer Cell* **19**, 31-44 (2011).
192. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. *Oncologist* **9 Suppl 1**, 11-18 (2004).
193. Hurwitz H, *et al.* Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* **350**, 2335-2342 (2004).
194. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. *Ann N Y Acad Sci* **1131**, 225-234 (2008).
195. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). *Int J Biochem Cell Biol* **33**, 409-420 (2001).
196. Eriksson A, *et al.* Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers. *Cancer Cell* **1**, 99-108 (2002).
197. Teicher BA. Newer vascular targets: endosialin (review). *Int J Oncol* **30**, 305-312 (2007).
198. Oh P, *et al.* Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. *Nature* **429**, 629-635 (2004).
199. O'Shannessy DJ, Somers EB, Chandrasekaran LK, Nicolaides NC, Bordeaux J, Gustavson MD. Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins. *Oncotarget* **5**, 3983-3995 (2014).
200. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. *Cancer Res* **61**, 6649-6655 (2001).
201. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* **9**, 669-676 (2003).
202. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. *Nat Med* **7**, 987-989 (2001).
203. Willett CG, *et al.* Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. *Nat Med* **10**, 145-147 (2004).
204. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. *Cancer Res* **64**, 3731-3736 (2004).

205. Lee TH, Avraham H, Lee SH, Avraham S. Vascular endothelial growth factor modulates neutrophil transendothelial migration via up-regulation of interleukin-8 in human brain microvascular endothelial cells. *J Biol Chem* **277**, 10445-10451 (2002).
206. Inai T, *et al.* Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. *Am J Pathol* **165**, 35-52 (2004).
207. Zhang DF, *et al.* Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 4117-4122 (2011).
208. Bruns CJ, *et al.* Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. *International Journal of Cancer* **102**, 101-108 (2002).
209. Byrne AT, *et al.* Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. *Clinical Cancer Research* **9**, 5721-5728 (2003).
210. Zips D, *et al.* Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. *Anticancer Research* **23**, 3869-3876 (2003).
211. Roberts N, *et al.* Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. *Cancer Research* **66**, 2650-2657 (2006).
212. Tammela T, *et al.* Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature* **454**, 656-660 (2008).
213. Fischer C, *et al.* Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell* **131**, 463-475 (2007).
214. Bais C, *et al.* PlGF blockade does not inhibit angiogenesis during primary tumor growth. *Cell* **141**, 166-177 (2010).
215. Osman J, Galli S, Hanafy M, Tang X, Ahmed A. Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: a pilot study. *Clin Transl Oncol* **15**, 953-958 (2013).
216. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. *J Natl Cancer Inst* **86**, 356-361 (1994).
217. Salgado R, Benoy I, Vermeulen P, van Dam P, Van Marck E, Dirix L. Circulating basic fibroblast growth factor is partly derived from the tumour in patients with colon, cervical and ovarian cancer. *Angiogenesis* **7**, 29-32 (2004).
218. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. *J Cell Physiol* **151**, 81-93 (1992).
219. Ji H, *et al.* TNFR1 mediates TNF-alpha-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling. *Nat Commun* **5**, 4944 (2014).
220. Cao RH, *et al.* Hepatocyte growth factor is a lymphangiogenic factor with an indirect mechanism of action. *Blood* **107**, 3531-3536 (2006).